WO2008117229A1 - Muscarinic receptor antagonists - Google Patents

Muscarinic receptor antagonists Download PDF

Info

Publication number
WO2008117229A1
WO2008117229A1 PCT/IB2008/051088 IB2008051088W WO2008117229A1 WO 2008117229 A1 WO2008117229 A1 WO 2008117229A1 IB 2008051088 W IB2008051088 W IB 2008051088W WO 2008117229 A1 WO2008117229 A1 WO 2008117229A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ethyl
benzodioxol
azoniabicyclo
cyano
Prior art date
Application number
PCT/IB2008/051088
Other languages
French (fr)
Other versions
WO2008117229A4 (en
Inventor
Naresh Kumar
Kirandeep Kaur
Malvika Garg
Venkata P. Palle
Mohammad Salman
Abhijit Ray
Suman Gupta
Shivani Malhotra
Rajkumar Shirumalla
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2008117229A1 publication Critical patent/WO2008117229A1/en
Publication of WO2008117229A4 publication Critical patent/WO2008117229A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Definitions

  • the present invention relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
  • the invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.
  • compositions comprising one or more muscarinic receptor antagonists and at least one or more therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR (epidermal growth factor receptor) kinase inhibitors, PAF (platelet activating factor) antagonists, 5-lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP Kinase inhibitors.
  • therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR (epidermal growth factor receptor) kinase inhibitors, PAF (platelet activating factor) antagonists, 5-lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP Kinase inhibitors.
  • acetylcholine receptors the nicotinic and muscarinic acetylcholine receptors.
  • Muscarinic receptors belong to the superfamily of G-protein coupled receptors and five molecularly distinct subtypes are known to exist (M 1 , M 2 , M 3 , M 4 and M 5 ). These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission.
  • the M 1 subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia
  • the M 2 subtype is present mainly in the heart and bladder smooth muscle
  • the M 3 subtype is located predominantly on smooth muscle and salivary glands ⁇ Nature, 323, p.411 (1986); Science, 237, p.527 (1987)).
  • M 2 and M 3 receptors are the predominant cholinoreceptors, the smaller population of M 3 - receptors appears to be the most functionally important as they mediate the direct contraction of these smooth muscles.
  • Muscarinic receptor antagonists are known to be useful for treating various medical conditions associated with improper smooth muscle function, such as overactive bladder syndrome, irritable bowel syndrome and chronic obstructive pulmonary disease.
  • overactive bladder syndrome irritable bowel syndrome
  • chronic obstructive pulmonary disease a chronic obstructive pulmonary disease.
  • antimuscarinics has been limited by poor tolerability as a result of treatment related, frequent systemic adverse events such as dry mouth, constipation, blurred vision, headache, somnolence and tachycardia.
  • novel muscarinic receptor antagonists that demonstrate target organ selectivity.
  • WO 2004/005252 discloses azabicyclo derivatives described as musacrinic receptor antagonists.
  • WO 2004/014853, and WO 2004/014363 disclose 3, 6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists;
  • WO 2004/056811 discloses flaxavate derivatives as muscarinic receptor antagonists;
  • WO 2004/056810 discloses xanthene derivatives as muscarinic receptor antagonists;
  • WO 2004/056767 discloses 1-substituted- 3-pyrrolidine derivatives as muscarinic receptor antagonists;
  • WO 99/14200, WO 03/027060, US 6,200, 991, and WO 00/56718 disclose heterocycle derivatives as muscarinic receptor antagonists;
  • WO 2004/089363, WO 2004/089898, WO 2004/069835, WO 2004/089900 and WO 2004/089364 disclose substituted azabicyclohexane derivatives as muscarinic receptor antagonists;
  • Chem., 34, p.3065 (1991) describes analogues of oxybutynin, synthesis and antimuscarinic activity of some substituted 7-amino-l-hydroxy-5-heptyn-2-ones and related compounds.
  • Bio-Organic Medicinal Chemistry Letters, 15, p.2093 (2005) describes synthesis and activity of analogues of Oxybutynin and Tolterodine, Chem. Pharm. Bull. 5 ⁇ 3(4), 437, 2005 discloses thiazole carboxamide derivatives.
  • muscarinic receptor antagonists of Formula I and Formula Ia which can be effective therapeutic or prophylactic agent for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems. Also provided are processes for synthesizing such compounds.
  • compositions containing such compounds are provided together with acceptable carriers, excipients or diluents which can be useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems.
  • acceptable carriers, excipients or diluents which can be useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems.
  • the enantiomers, diastereomers, N-oxides, polymorphs, and pharmaceutically acceptable solvates of these compounds as well as metabolites having the same type of activity are also provided, as well as pharmaceutical compositions comprising the compounds, their metabolites, enantiomers, diastereomers, N-oxides, polymorphs or solvates thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.
  • compositions comprising one or more muscarinic receptor antagonists of Formula I or Formula Ia and at least one or more therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR kinase inhibitors, PAF antagonists, 5 -lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP kinase inhibitors.
  • therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR kinase inhibitors, PAF antagonists, 5 -lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP kinase inhibitors.
  • the present invention relates to compounds having the structure of Formula I and Formula Ia:
  • ⁇ ⁇ y represents a nitrogen containing cyclic ring having 5-9 carbon atoms and T is a bridging group selected from the group consisting of -(CH 2 ) n -, -CH(Q)CH 2 -, - CH 2 CH(Q)CH 2 -, -CH(Q)-, -CH 2 -O-CH 2 - or -CH 2 -NH-CH 2 -; n can be an integer selected from 0-3 (wherein when n is zero then T represents a direct bond);
  • Q can be alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl or heterocyclylalkyl;
  • m can be an integer selected from 1-4;
  • Ri and R 2 can be independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl;
  • R 3 can be cyano, -CONR x R 5 ,, -COOR x , hydroxy, alkoxy, -(CH 2 ) m OR x , -(CH 2 ) m 0C0R x , - (CH 2 ) m NHR x , -(CH 2 ) m NHC0R x , -(CH 2 ) m NR x SO 2 R w ;
  • R x and R y can be independently selected from hydrogen, alkyl, cycloalkyl, aryl, halogen, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; R x and R y may also together join to form a heterocyclyl ring;
  • R w can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl or heteroarylalkyl;
  • R q can be alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl or aralkyl;
  • R 1 can be alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl or aralkyl;
  • Z " can be an anion selected from bromide, chloride, iodide, tartrate, sulphate, phosphate, nitrate, carbonate, fumarate, glutamate, citrate, methanesulphonate, benzenesulphonate, maleate and succinate.
  • the invention encompasses compounds of Formula I and
  • Formula Ia which may include, but not limited to the following:
  • Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3- en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 51); Bromide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-benzyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 52);
  • Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(4-cyano- 4,4-diphenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 68); Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2- cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 69);
  • composition comprising therapeutically effective amount of compound of Formula I or Formula Ia described herein together with one or more pharmaceutically acceptable carrier(s), excipients(s) or diluent(s).
  • a method for treatment or prophylaxis of a mammal suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors includes administration of at least one compound having the structure of Formula I or Formula Ia.
  • a method for treatment or prophylaxis of a mammal suffering from a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like, urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc. and gastrointestinal system such as irritable bowel syndrome, gastrointestinal hyperkinesis, obesity and diabetes with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors.
  • a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like
  • urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc.
  • gastrointestinal system such as irritable bowel syndrome, gastrointestinal hyperkinesis, obesity and diabetes with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors.
  • a pharmaceutical composition comprising one or more muscarinic receptor antagonist compound having the structure of Formula I or Formula Ia as defined above and at least one or more therapeutic agent selected from histamine antagonist, corticosteroids, beta agonist, leukotriene antagonist, EGFR kinase inhibitors, PAF antagonist, 5-lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p-38 MAP kinase inhibitors.
  • processes for preparing the compounds as described above are provided.
  • alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms.
  • This term can be exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n- decyl, tetradecyl, and the like.
  • alkylene refers to a diradical branched or unbranched saturated hydrocarbon chain having from 1 to 6 carbon atoms and one or more hydrogen can optionally be substituted with alkyl, hydroxy, halogen or oximes. This term can be exemplified by groups such as methylene, ethylene, propylene isomers (e.g., -CH 2 CH 2 CH 2 and -CH(CHs)CH 2 ) and the like.
  • alkenyl refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms with cis, trans or geminal geometry.
  • Alkenyl groups can be optionally interrupted by atom(s) or group(s) independently chosen from oxygen, sulfur, phenylene, sulphinyl, sulphonyl and -NR ⁇ - (wherein R ⁇ is the same as defined earlier). In the event that alkenyl is attached to a heteroatom, the double bond cannot be alpha to the heteroatom.
  • alkynyl refers to a monoradical of an unsaturated hydrocarbon, having from 2 to 20 carbon atoms.
  • Alkynyl groups can be optionally interrupted by atom(s) or group(s) independently chosen from oxygen, sulfur, phenylene, sulphinyl, sulphonyl and -NR ⁇ - (wherein R ⁇ is the same as defined earlier). In the event that alkynyl groups are attached to a heteroatom, the triple bond cannot be alpha to the heteroatom.
  • cycloalkyl refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, which may optionally contain one or more olefinic bonds, unless otherwise constrained by the definition.
  • Such cycloalkyl groups can include, for example, single ring structures, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, and the like or polycyclic ring structures such as, adamantyl, tricyclo[3.3.1.1]decane, bicyclo[2.2.2]octane, bicyclo[4.4.0]decane, bicyclo- [4.3.0]nonane, bicyclo[3.3.0]octane, bicyclo[2.2.1]heptane and the like, or cyclic alkyl groups to which is fused an aryl group, for example, indane, and the like.
  • Cycloalkylalkyl refers to alkyl-cycloalkyl group linked through alkyl portion, wherein the alkyl and cycloalkyl are the same as defined earlier.
  • alkoxy denotes the group O-alkyl, wherein alkyl is the same as defined above.
  • aryl unless otherwise specified, refers to aromatic system having 6 to
  • aryl groups include, but are not limited to, phenyl, biphenyl, anthryl or naphthyl ring and the like, optionally substituted with 1 to 3 substituents selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, acyl, aryloxy, CF 3 , cyano, nitro, -CHO, OCF 3 , -SCF 3 , COOR ⁇ ,
  • halogen e.g., F, Cl, Br, I
  • Aryl groups optionally may be fused with a cycloalkyl group or a heteroaryl group, wherein the cycloalkyl group may optionally contain heteroatoms selected from O, N or S.
  • Groups such as phenyl, naphthyl, anthryl, biphenyl, and the like exemplify this term.
  • aralkyl refers to alkyl-aryl linked through an alkyl portion (wherein alkyl is as defined above) and the alkyl portion contains 1-6 carbon atoms and aryl is as defined below.
  • alkyl groups include benzyl, ethylphenyl, propylphenyl, naphthylmethyl and the like.
  • aryloxy denotes the group O-aryl, wherein aryl is as defined above.
  • heteroaryl refers to an aromatic monocyclic, bicyclic or a tricyclic ring system (they can be fused, spiro or bridged) containing 1-8 heteroatom(s) independently selected from N, O or S optionally substituted with 1 to 4 substituent(s) selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, acylamino, thiocarbonyl, , substituted thiocarbonyl, thioacyl, oxo, -CHO, -OCF 3 , -CF 3 , -SCF 3 , carboxy, aryl, alkoxy, alkoxyamin
  • heteroaryl groups includes but are not limited to are benzimidazolyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, benzoxazolyl, benzothiazolyl, benzothienyl, benzo- triazolyl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dioxanyl, dioxolanyl, furyl, homopiperidinyl, imidazolyl, imidazolinyl, imidazolidinyl, indolinyl, indolyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, napthyridinyl, oxazolidiny
  • halogen or halo refers to fluorine, chlorine, bromine or iodine.
  • haloalkyl refers to alkyl of which one or more hydrogen(s) is/are replaced by halogen.
  • heterocyclyl refers to a non-aromatic monocyclic or polycyclic ring (fused, spiro or bridged) system having 1 to 8 heteroatoms selected from O, S or N, and optionally are benzofused or fused heteroaryl having 5-6 ring members and/or optionally are substituted, wherein the substituents are selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, acylamino, optionally substituted thiocarbonyl, optionally substituted aryl, alkoxy, alkoxyamino, alkaryl, cyano, nitro, oxo, -C ⁇ O, -OCF 3 , -CF 3 , -SCF 3 , carboxy, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl
  • Heterocyclyl can optionally include rings having one or more double bonds. Such ring systems can be mono-, bi- or tricyclic. Carbonyl or sulfonyl group can replace carbon atom(s) of heterocyclyl. Unless otherwise constrained by the definition, the substituents are attached to the ring atom, i.e., carbon or heteroatom in the ring. Also, unless otherwise constrained by the definition, the heterocyclyl ring optionally may contain one or more olefinic bond(s).
  • heterocyclyl groups includes but are not limited to are tetrahydrofuranyl, dihydrofuranyl, dihydropyridinyl, dihydrobenzofuryl, azabicyclohexyl, dihydroindolyl, piperidinyl, isoxazolinyl, thiazolinyl, thiazolidinonyl, oxazolinyl, oxazolidinonyl, azabicyclo[3.1.0]hexyl, diazabicyclo[2.2.1]heptyl, azetidinyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, dihydrobenzofuryl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dihydroindolyl, dihydroisoxazolyl, dihydropyridinyl, dioxanyl, dioxolanyl, homop
  • Heteroarylalkyl refers to alkyl-heteroaryl group linked through alkyl portion, wherein the alkyl and heteroaryl are as defined earlier.
  • Heterocyclylalkyl refers to alkyl-heterocyclyl group linked through alkyl portion, wherein the alkyl and heterocyclyl are as defined earlier.
  • pharmaceutically acceptable carriers is intended to include non- toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • Protecting Groups is used herein to refer to known moieties, which have the desirable property of preventing specific chemical reaction at a site on the molecule undergoing chemical modification intended to be left unaffected by the particular chemical modification.
  • protecting group unless or other specified may be used with groups such as hydroxy, amino, carboxy and example of such groups are found in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2 nd Edn. John Wiley and Sons, New York, N. Y., which is incorporated herein by reference.
  • the species of the carboxylic protecting groups, amino protecting groups or hydroxy protecting group employed is not so critical so long as the derivatised moiety/moieties is/are stable to conditions of subsequent reactions and can be removed at the appropriate point without disrupting the remainder of the molecule.
  • the compounds described herein exhibit significant potency in terms of their activity, as determined by in vitro receptor binding and functional assays and in vivo experiments.
  • the compounds that were found active in vitro were tested in vivo.
  • Some of the compounds are potent muscarinic receptor antagonists with high affinity towards M 1 and M 3 receptors than M 2 and/or M 5 receptors. Therefore, pharmaceutical compositions for the possible treatment for the disease or disorders associated with muscarinic receptors are provided.
  • the compounds of Formula IV, IVa, IVb, V and VII can be prepared following the procedure as described in Scheme I.
  • Compound of Formula II can be reacted with a compound of Formula III to give a compound of Formula IV in one or more organic solvent (for example, dimethylformamide, toluene, tetrahydrofuran, diethylether) in the presence of one or more base (for example, sodium hydride or sodium methoxide).
  • organic solvent for example, dimethylformamide, toluene, tetrahydrofuran, diethylether
  • base for example, sodium hydride or sodium methoxide
  • the reduction of a compound of Formula IV(when Gi is -CN) to give a compound of Formula IVa can be carried out in the presence of reducing agent (for example, lithium aluminum hydride, sodium borohydride, diisobutyl aluminum hydride) in the presence of one or more solvent (for example, diethylether, tetrahydrofuran, dimethylformamide).
  • reducing agent for example, lithium aluminum hydride, sodium borohydride, diisobutyl aluminum hydride
  • solvent for example, diethylether, tetrahydrofuran, dimethylformamide
  • mixed hydrides for example, lithium aluminum hydride and aluminum chloride.
  • the hydrolysis of compound IV (when G 1 is -COOalkyl) to give a compound of Formula IVb can be carried out in the presence of one or more base (for example, lithium hydroxide, sodium hydroxide or potassium hydroxide) in the presence of one or more solvent (for example methanol, ethanol or isopropyl alcohol).
  • one or more base for example, lithium hydroxide, sodium hydroxide or potassium hydroxide
  • solvent for example methanol, ethanol or isopropyl alcohol
  • the deprotection of a compound of Formula IV (wherein P is aralkyl) to give a compound of Formula V can be carried out in one or more solvent (for example, methanol, ethanol, propanol or isopropyl alcohol) in the presence of a deprotecting agent (for example, palladium on carbon in presence of hydrogen gas or palladium on carbon in ammonium formate solution).
  • a deprotecting agent for example, palladium on carbon in presence of hydrogen gas or palladium on carbon in ammonium formate solution.
  • one or more base for example, potassium hydroxide, sodium hydroxide or lithium hydroxide
  • solvent for example, methanol, ethanol, propanol or isopropyl alcohol.
  • solvent for example, methanol, ethanol, propanol or isopropylalcohol
  • a deprotecting agent for example, palladium on carbon in presence of hydrogen gas or palladium on carbon with a source of hydrogen gas (for example, ammonium formate solution, cyclohexene or formic acid).
  • an alcohol for example, hydrochloric acid solution of methanol, ethanol, propanol, isopropylalcohol, ethylacetate or diethylether
  • trifluoroacetic acid in dichloromethane.
  • a supernucleophile for example, lithium cobalt (I) phthalocyanine, zinc and acetic acid or cobalt phthalocyanine.
  • the compound of Formula IV (when Gi is -CN) can be converted to a compound of Formula VI with sulphuric acid.
  • the conversion of the compound of Formula IV to give a compound of Formula VI may also be carried out with sodium hydroxide in the presence of hydrogen peroxide.
  • the compounds of Formula IX can be prepared following the procedure as depicted in Scheme II.
  • the compound of Formula VIII (wherein R 1 , R 2 , R 3 , m and T are the same as defined earlier) can be reacted with compound of Formula R a -hal (wherein R a is alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aralkyl or cycloalkyl and hal is the same as defined earlier) to give a compound of Formula IX.
  • the compound of Formula VIII can be reacted with a compound of Formula R a -hal to give a compound of Formula IX in one or more solvent (for example, acetonitrile, dichloromethane, chloroform or carbon tetrachloride) optionally in the presence of one or more base (for example, potassium carbonate, potassium iodide or sodium carbonate).
  • solvent for example, acetonitrile, dichloromethane, chloroform or carbon tetrachloride
  • base for example, potassium carbonate, potassium iodide or sodium carbonate
  • esters are specified, one skilled in the art could optionally hydrolyze them to their respective acids.
  • hydrolysis of alkyl esters such as ethyl, methyl or benzyl ester
  • hydrolysis of benzyl ester can be carried out using catalysts, for example, palladium on carbon or platinum on carbon.
  • the esters such as tert-buty ⁇ can be hydrolyzed to their corresponding acids in the presence of acid, for example, trifluoroacetic acid or hydrochloric acid.
  • the compounds of Formula IXa can be prepared following the procedure as described in Scheme III.
  • the compound of Formula Villa (wherein T, m, R 1 , R 2 and R 3 are the same as defined earlier; R k is alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aralkyl or cycloalkyl) can be reacted with compound of Formula R v -hal (wherein hal is Br, Cl or I and R v is alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl or aralkyl) to give compound of Formula IXa
  • reaction of a compound of Formula Villa with compound of Formula Rv-hal can be carried out optionally in an organic solvent for example, dichloromethane, dichloroethane, carbon-tetrachloride, chloroform, acetonitrile, methanol or mixture(s) thereof.
  • organic solvent for example, dichloromethane, dichloroethane, carbon-tetrachloride, chloroform, acetonitrile, methanol or mixture(s) thereof.
  • Bromide salt of -3-benzyl-6- (2-cyano-2,2-diphenylethyl)-3-(4-methylpent-3-en-l- yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 46); Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2,2-diphenylethyl)-3-(4- methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 47);
  • compositions of the present invention may be administered by following routes, for example, oral, topical, intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, subcutaneous, intranasally, inhalation, rectally or vaginally.
  • the compounds described herein can be produced and formulated as their enantiomers, diastereomers, N-Oxides, polymorphs, solvates, as well as metabolites having the same type of activity.
  • Pharmaceutical compositions comprising the molecules of Formula I or Formula Ia or metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates thereof, in combination with pharmaceutically acceptable carrier and optionally included excipient can also be produced.
  • the compounds of Formula I or Formula Ia and/or their pharmaceutically acceptable solvates, stereoisomers, prodrugs, metabolites, polymorphs or N-oxides may be advantageously used in combination with one or more other therapeutic agents.
  • other therapeutic agents which may be used in combination with compounds of Formula I or Formula Ia of this invention and/or their pharmaceutically acceptable solvates, stereoisomers, prodrugs, metabolites, polymorphs or N-oxides include but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5 -lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors and PDE-IV inhibitors.
  • Example Ia Synthesis of ethyl 3-(3-benzyl-3-azabicyclor3.1.01hex-6-yl)-2,2- diphenylpropanoate (Compound No. 9)
  • Example 2 Synthesis of 3-(3-azabicyclor3.1.01hex-6-yl)-2,2-diphenylpropanenitrile (Compound No. 2) To a solution of the compound No. 1 (330 mg, 0.87 mmol) in methanol (about 10 ml) was added palladium on carbon (20% w/w) and ammonium formate (338 mg) and refluxed the reaction mixture for about one hour. The reaction mixture was cooled to 25 0 C and filtered through celite pad. The celite bed was washed with methanol. Filtrate was evaporated under reduced pressure and the residue thus obtained was dissolved in water, basified with aqueous sodium hydroxide solution and extracted with dichloromethane.
  • Compound No. 2 To a solution of the compound No. 1 (330 mg, 0.87 mmol) in methanol (about 10 ml) was added palladium on carbon (20% w/w) and ammonium formate (338 mg) and refluxed the reaction mixture for about one
  • the compound No. 1 (520 mg) was dissolved in sulphuric acid solution (70 %, 7 ml) and the mixture was heated at about 80 0 C for about one hour.
  • the reaction mixture was poured into ice and basified with cold aqueous sodium hydroxide solution.
  • the mixture was extracted with ethyl acetate, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.
  • the residue thus obtained was purified by column chromatography using 1 % triethylamine in ethyl acetate as eluent to furnish the title compound. Yield: 105.0 mg.
  • Example 6 Synthesis of iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-methyl-3- (4-methylpent-3-en-l-yl)-3-azoniabicyclor3.1.01hexane (Compound No. 11)
  • dichloromethane about 0.5 ml
  • methyl iodide ⁇ 3 mL, excess
  • the reaction mixture was concentrated under reduced pressure followed by the addition of diethyl ether.
  • the precipitates thus formed were washed with diethyl ether. Supernatant was decanted off and the precipitates were dried under reduced pressure to furnish the title compound. Yield: 55.0 mg.
  • reaction mixture was poured into ice and basified with aqueous sodium hydroxide (10%) and extracted with ethyl acetate. The organic layer was separated, washed, dried and concentrated to get the crude compound.
  • the crude compound was purified by column chromatography. Yield: 46.0 mg.
  • Membrane preparation Submandibular glands and heart were isolated and placed in ice- cold homogenizing buffer (HEPES 2OmM, 1OmM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenized in 10 volumes of homogenizing buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for 10 min. at 4 0 C. The supernatant was subsequently centrifuged at 40,00Og for 20 min. at 4 0 C. The pellet thus obtained was resuspended in assay buffer (HEPES 20 mM,
  • Ligand binding assay The compounds were dissolved and diluted in DMSO. The membrane homogenates (150-250 ⁇ g protein) were incubated in 250 ⁇ l of assay volume
  • pKi is -log [Ki].
  • the tested compounds exhibited Ki at m3 receptor is in the range of about 1 nM to about 1000 ⁇ M
  • ED 50 values are calculated by fitting a non-linear regression curve (Graph Pad Prism).
  • the tissue was equilibrated for 1 hr for stabilization. After 1 hr, the tissue was challenged with IuM carbachol. This was repeated after every 2-3 washes till two similar consecutive responses were obtained. At the end of stabilization, the tissue was washed for 30 minutes followed by incubation with suboptimal dose of MRA/Vehicle for 20 minutes prior to contraction of the tissues with l ⁇ M carbachol.
  • the contractile response of tissues was recorded either on Powerlab data acquisition system or on Grass polygraph (Model 7).
  • the relaxation was expressed as percentage of maximum carbachol response.
  • the data was expressed as mean ⁇ s.e. mean for n observations.
  • the EC 50 was calculated as the concentration producing 50% of the maximum relaxation to l ⁇ M carbachol.
  • the percent relaxation was compared between the treated and control tissues using non-parametric unpaired t-test. A p value of ⁇ 0.05 was considered to be statistically significant.
  • the tested compounds exhibited a pKb in the range of about 8.7 to about 10.5 nM In-vitro functional assay to evaluate efficacy of "MRA" in combination with "PDE-IV inhibitors"
  • Trachea tissue is obtained from a guinea pig (400-600gm) under anesthesia (sodium pentobarbital, 300 mg/kg i.p) and is immediately kept in an ice-cold Krebs Henseleit buffer. Indomethacin (lOuM) is present throughout the KH buffer to prevent the formation of bronchoactive prostanoids.
  • Trachea tissue is cleaned off adherent fascia and cut it into strips of equal size (with approx. 4-5 tracheal rings in each strip).
  • the epithelium is removed by careful rubbing, minimizing damage to the smooth muscle.
  • the trachea is opened along the mid- dorsal surface with the smooth muscle band intact and a series of transverse cuts is made from alternate sides so that they do not transect the preparation completely. Opposite ends of the cut rings are tied with the help of a thread.
  • the tissue is mounted in isolated tissue baths containing 10 mL Krebs Henseleit buffer maintained at 37°C and is bubbled with carbogen, at a basal tension of 1 gm.
  • the buffer is changed 4-5 times for about an hour and the tissue is equilibrated for 1 hour for stabilization. After 1 hour, the tissue is contacted with IuM carbachol. Repeat this after every 2-3 washes until two similar consecutive responses are obtained. At the end of stabilization, the tissue is washed for 30 minutes followed by incubation with suboptimal dose of MRA/Vehicle for 20 minutes prior to contraction of the tissues with l ⁇ M carbachol.
  • the relaxant activity of the PDE- IV inhibitor [10 ⁇ 9 M to 10 "4 M ] on the stabilized developed tension/response is assessed.
  • the contractile response of tissues is recorded either on a Powerlab data acquisition system or on a Grass polygraph (Model 7).
  • the relaxation is expressed as a percentage of maximum carbachol response.
  • the data is expressed as mean ⁇ s.e. mean for n observations.
  • the EC 50 is calculated as the concentration producing 50% of the maximum relaxation to l ⁇ M carbachol.
  • the percent relaxation between the treated and control tissues is compared using non-parametric unpaired t-test. A p value of ⁇ 0.05 is considered to be statistically significant.
  • MRA (l ⁇ g/kg to lmg/kg) and PDE-IV inhibitor (l ⁇ g/kg to lmg/kg) are instilled intratracheally under anesthesia either alone or in combination.
  • mice Male wistar rats weighing 200 ⁇ 20gm are used in the study. Rats have free access to food and water. On the day of experiment, animals are exposed to lipopolysaccharide (LPS, lOO ⁇ g/ml) for 40 min. One group of vehicle treated rats is exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals are placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing acetylcholine (1, 6, 12, 24, 48 and 96 mg/ml) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone.
  • LPS lipopolysaccharide
  • PBS phosphate buffered saline
  • PCIOO LPS PClOO in untreated LPS challenged group
  • PCIOO TEST PClOO in group treated with a given dose of test compound
  • PClOOpBs PClOO in group challenged with PBS
  • BAL bronchoalveolar lavage
  • NCLPS - NCTEST % Inhibition X 100
  • NCLPS Percentage of neutrophil in untreated LPS challenged group
  • NC TEST Percentage of neutrophil in group treated with a given dose of test compound
  • NC CON Percentage of neutrophil in group not challenged with LPS
  • Guinea pigs are sensitized on days 0, 7 and 14 with 50- ⁇ g ovalbumin and 10 mg aluminum hydroxide injected intraperitoneally. On days 19 and 20 guinea pigs are exposed to 0.1% w v "1 ovalbumin or PBS for 10 min, and with 1% ovalbumin for 30 min on day 21. Guinea pigs are treated with test compound (0.1, 0.3 and 1 mg kg "1 ) or standard 1 mg kg "1 or vehicle once daily from day 19 and continued for 4 days. Ovalbumin / PBS challenge is performed 2 hours after different drug treatment.
  • BAL is performed using Hank's balanced salt solution (HBSS). Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Pellet is collected and resuspended in ImI HBSS. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and eosinophil count are expressed as cell count (millions cells ml "1 of BAL). Eosinophil is also expressed as percent of total leukocyte count. % inhibition is computed using the following formula.
  • EOS OVA Percentage of eosinophil in untreated ovalbumin challenged group
  • EOS TEST Percentage of eosinophil in group treated with a given dose of test compound
  • EoscoN Percentage of eosinophil in group not challenged with ovalbumin.
  • LPS Lipopoly saccharide
  • AHR airway hyper reactivity
  • neutrophilia Lipopoly saccharide induced airway hyper reactivity
  • MRA (l ⁇ g/kg to lmg/kg) and p38 MAP kinase inhibitor (l ⁇ g/kg to lmg/kg) are instilled intratracheally under anesthesia either alone or in combination.
  • mice Male wistar rats weighing 200 ⁇ 20gm are used in the study. Rats have free access to food and water. On the day of experiment, animals are exposed to lipopoly saccharide (LPS, lOO ⁇ g/ml) for 40 min. One group of vehicle treated rats is exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals are placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing acetylcholine (1, 6, 12, 24, 48 and 96 mg/ml) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone.
  • LPS lipopoly saccharide
  • PBS phosphate buffered saline
  • PCIOO LPS PClOO in untreated LPS challenged group
  • PCIOO TEST PClOO in group treated with a given dose of test compound
  • PClOOpBs PClOO in group challenged with PBS
  • BAL bronchoalveolar lavage
  • NCLPS — NCTEST % Inhibition X 100
  • NC LPS Percentage of neutrophil in untreated LPS challenged group
  • NC TEST Percentage of neutrophil in group treated with a given dose of test compound
  • NC CON Percentage of neutrophil in group not challenged with LPS
  • the percent inhibition data is used to compute ED 50 values using Graph Pad Prism software (Graphpad Software Inc. ,USA).
  • Drug treatment MRA (l ⁇ g/kg to lmg/kg) and long acting ⁇ 2 agonist is instilled intratracheally under anesthesia either alone or in combination.
  • Wistar rats 250-350gm or balb/C mice (20-30gm) is placed in body box of a whole body plethysmograph (Buxco Electronics., USA) to induce bronchoconstriction. Animals are allowed to acclimatize in the body box and are given successive challenges, each of 2 min duration, with PBS (vehicle for acetylcholine) or acetylcholine (i.e. 24, 48, 96, 144, 384, and 768 mg/ml). The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA) for 3 min. A gap of 2 min is allowed for the animals to recover and then challenged with the next higher dose of acetylcholine (ACh).
  • ACh acetylcholine
  • Penh values index of airway resistance
  • Penh, at any chosen dose of ACh is, expressed as percent of PBS response.
  • the Penh values thus calculated are fed into Graph Pad Prism software (Graphpad Software Inc., USA) and using a nonlinear regression analysis PClOO (2 folds of PBS value) values are computed. % inhibition is computed using the following formula.
  • PCIOO TEST PClOO in group treated with a given dose of test compound

Abstract

The present invention relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists and at least one or more therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR kinase inhibitors, PAF antagonists, 5-lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP Kinase inhibitors.

Description

MUSCARINIC RECEPTOR ANTAGONISTS
Field of the Invention
The present invention relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists and at least one or more therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR (epidermal growth factor receptor) kinase inhibitors, PAF (platelet activating factor) antagonists, 5-lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP Kinase inhibitors.
Background of the Invention Physiological effects elicited by the neurotransmitter acetylcholine are mediated through its interaction with two major classes of acetylcholine receptors - the nicotinic and muscarinic acetylcholine receptors. Muscarinic receptors belong to the superfamily of G-protein coupled receptors and five molecularly distinct subtypes are known to exist (M1, M2, M3, M4 and M5). These receptors are widely distributed on multiple organs and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented (for example, the M1 subtype is located primarily in neuronal tissues such as cereberal cortex and autonomic ganglia, the M2 subtype is present mainly in the heart and bladder smooth muscle, and the M3 subtype is located predominantly on smooth muscle and salivary glands {Nature, 323, p.411 (1986); Science, 237, p.527 (1987)).
A review in Curr. Opin. Chem. Biol, 3, p. 426 (1999), as well as in Trends in Pharmacol. ScL, 22, p. 409 (2001) by Eglen et. al., describes the biological potentials of modulating muscarinic receptor subtypes by ligands in different disease conditions, such as Alzheimer's disease, pain, urinary disease condition, chronic obstructive pulmonary disease, and the like.
The pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists are presented in a review in Molecules, 6, p. 142 (2001). Birdsall et. al. in Trends in Pharmacol. ScL, 22, p. 215 (2001) has also summarized the recent developments on the role of different muscarinic receptor subtypes using different muscarinic receptor of knock out mice.
Almost all the smooth muscles express a mixed population of M2 and M3 receptors. Although the M2- receptors are the predominant cholinoreceptors, the smaller population of M3- receptors appears to be the most functionally important as they mediate the direct contraction of these smooth muscles. Muscarinic receptor antagonists are known to be useful for treating various medical conditions associated with improper smooth muscle function, such as overactive bladder syndrome, irritable bowel syndrome and chronic obstructive pulmonary disease. However the therapeutic utility of antimuscarinics has been limited by poor tolerability as a result of treatment related, frequent systemic adverse events such as dry mouth, constipation, blurred vision, headache, somnolence and tachycardia. Thus, there exists a need for novel muscarinic receptor antagonists that demonstrate target organ selectivity.
WO 2004/005252 discloses azabicyclo derivatives described as musacrinic receptor antagonists. WO 2004/004629, WO 2004/052857, WO 2004/067510, WO
2004/014853, and WO 2004/014363 disclose 3, 6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists; WO 2004/056811 discloses flaxavate derivatives as muscarinic receptor antagonists; WO 2004/056810 discloses xanthene derivatives as muscarinic receptor antagonists; WO 2004/056767 discloses 1-substituted- 3-pyrrolidine derivatives as muscarinic receptor antagonists; WO 99/14200, WO 03/027060, US 6,200, 991, and WO 00/56718 disclose heterocycle derivatives as muscarinic receptor antagonists; WO 2004/089363, WO 2004/089898, WO 2004/069835, WO 2004/089900 and WO 2004/089364 disclose substituted azabicyclohexane derivatives as muscarinic receptor antagonists; WO 2006/018708 discloses pyrrolidine derivatives as muscarinic receptor antagonists; and WO 2006/035303 discloses azabicyclo derivatives as muscarinic receptor antagonists. /. Med. Chem., 44, p. 984 (2002) describes cyclohexylmethylpiperidinyl- triphenylpropioamide derivatives as selective M3 antagonist discriminating against the other receptor subtypes. /. Med. Chem., 36, p. 610 (1993) describes the synthesis and antimuscarinic activity of some l-cycloalkyl-l-hydroxy-l-phenyl-3-(4-substituted piperazinyl)-2-propanones and related compounds. /. Med. Chem., 34, p.3065 (1991) describes analogues of oxybutynin, synthesis and antimuscarinic activity of some substituted 7-amino-l-hydroxy-5-heptyn-2-ones and related compounds. Bio-Organic Medicinal Chemistry Letters, 15, p.2093 (2005) describes synthesis and activity of analogues of Oxybutynin and Tolterodine, Chem. Pharm. Bull. 5^3(4), 437, 2005 discloses thiazole carboxamide derivatives.
Summary of the Invention
According to one aspect, there are provided muscarinic receptor antagonists of Formula I and Formula Ia, which can be effective therapeutic or prophylactic agent for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems. Also provided are processes for synthesizing such compounds.
According to another aspect, pharmaceutical compositions containing such compounds are provided together with acceptable carriers, excipients or diluents which can be useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems. The enantiomers, diastereomers, N-oxides, polymorphs, and pharmaceutically acceptable solvates of these compounds as well as metabolites having the same type of activity are also provided, as well as pharmaceutical compositions comprising the compounds, their metabolites, enantiomers, diastereomers, N-oxides, polymorphs or solvates thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.
Also provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists of Formula I or Formula Ia and at least one or more therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR kinase inhibitors, PAF antagonists, 5 -lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP kinase inhibitors. Other aspects will be set forth in the description which follows, and in part will be apparent from the description or may be learnt by the practice of the invention.
Detailed Description of the Invention
The present invention relates to compounds having the structure of Formula I and Formula Ia:
Figure imgf000005_0001
and its pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, metabolites or N-oxides wherein
\^y represents a nitrogen containing cyclic ring having 5-9 carbon atoms and T is a bridging group selected from the group consisting of -(CH2)n-, -CH(Q)CH2-, - CH2CH(Q)CH2-, -CH(Q)-, -CH2-O-CH2- or -CH2-NH-CH2-; n can be an integer selected from 0-3 (wherein when n is zero then T represents a direct bond);
Q can be alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl or heterocyclylalkyl; m can be an integer selected from 1-4; Ri and R2 can be independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl;
R3 can be cyano, -CONRxR5,, -COORx, hydroxy, alkoxy, -(CH2)mORx, -(CH2)m0C0Rx, - (CH2)mNHRx, -(CH2)mNHC0Rx, -(CH2)mNRxSO2Rw;
Rx and Ry can be independently selected from hydrogen, alkyl, cycloalkyl, aryl, halogen, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; Rx and Ry may also together join to form a heterocyclyl ring;
Rz can be hydrogen, Rq, alkoxy, aryloxy, -C(=0)NRxRy, -0C(=0)NRxRy, -COOR2, - SO2R3, -NRwSO2Rw, -CN, acyl, -NRxC(=0)0Ry, halogen, hydroxy or -NHC(=O)RW; Rw can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl or heteroarylalkyl;
Rq can be alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl or aralkyl; R1 can be alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl or aralkyl;
Z" can be an anion selected from bromide, chloride, iodide, tartrate, sulphate, phosphate, nitrate, carbonate, fumarate, glutamate, citrate, methanesulphonate, benzenesulphonate, maleate and succinate. In another embodiment, the invention encompasses compounds of Formula I and
Formula Ia, which may include, but not limited to the following:
3-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenyrpropanenitrile (Compound
No. 1);
3-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanenitrile (Compound No. 2); 3-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanamide (Compound
No. 3);
3-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanamide (Compound No. 4);
Iodide salt of 3-[l-(l,3-benzodioxol-5-yl)methyl]-8-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 5); 3-[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]-2,2- diphenylpropanamide (Compound No. 6);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanamide (Compound No. 7);
3-{3-[2-(2,3-Dihydro-l-benzofuran-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanamide (Compound No. 8);
Ethyl 3-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanoate (Compound No. 9);
Hydrochloride salt of 3-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2- diphenylpropanoic acid (Compound No. 10); Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-methyl-3-(4-methylpent-3- en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 11); Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 12);
Iodide salt of 8-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- y^ethyll-S-methyl-S-azoniabicycloP^.lJoctane (Compound No. 13); 3-(3-Benzyl-3-azabicyclo[3.2. l]oct-8-yl)-2,2-diphenylpropanenitrile (Compound
No. 14);
3-(3-Azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanenitrile (Compound No. 15);
3-{3-[2-(2,3-Dihydro-l-benzofuran-6-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 16); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 17);
3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanenitrile (Compound No. 18);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanamide (Compound No. 19);
S-Q-AzabicycloP^.lJoct-S-yl^^-diphenylpropanamide (Compound No. 20);
3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanamide (Compound No. 21);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanamide (Compound No. 22);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropan-l-amine (Compound
No. 23);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Comp No. 24); 3-(3-Azabicyclo[3.2. l]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Compound
No. 25);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2-cyclohexyl-2- phenylpropanenitrile (Compound No. 26);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-cyclohexyl-2- phenylethylj-S-methyl-S-azoniabicycloP^.lJoctane (Compound No. 27);
Iodide salt of 3-benzyl-8-(2-cyano-2-cyclohexyl-2-phenylethyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 28); 2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanenitrile (Compound No. 29) ;
2-(3-Azabicyclo[3.2.1]oct-8-ylmethyl)-2-phenylbutanenitrile (Compound No. 30);
2-({3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}methyl)-2- phenylbutanenitrile (Compound No. 31);
2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanamide (Compound No. 32);
Iodide salt of 8-[2-(aminocarbonyl)-2-phenylbutyl]-3-benzyl-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 33); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 34);
Iodide salt of 3-benzyl-8-(2-cyano-2-phenylbutyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 35);
3-[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]-2,2- diphenylpropanenitrile
(Compound No. 36);
2-{[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2- phenylbutanenitrile (Compound No. 37);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanenitrile (Compound No. 38);
2-({3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}methyl)-2- phenylbutanenitrile (Compound No. 39);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 40); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2,2- diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 41);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2,2-diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 42);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 43);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2- phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 44); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2-phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 45) ;
Bromide salt of 3-benzyl-6- (2-cyano-2,2-diphenylethyl)-3-(4-methylpent-3-en-l- yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 46); Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2,2-diphenylethyl)-3-(4- methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 47);
Iodide salt of 6-(2-cyano-2, 2-diphenylethyl)-3-methyl-3-(4-methylpent-3-en-l-yl)- 3-azoniabicyclo[3.1.0]hexane (Compound No. 48);
Iodide salt of 6-(2-cyano-2-phenylbutyl)-3-methyl-3-(4-methylpent-3-en-l-yl)-3- azoniabicyclo[3.1.0]hexane (Compound No. 49);
Bromide salt of 3-benzyl-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3-en-l-yl)-3- azoniabicyclo[3.1.0]hexane (Compound No. 50);
Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3- en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 51); Bromide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-benzyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 52);
Iodide salt of 6-[2-(aminocarbonyl)-2-phenylbutyl]-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 53);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)- 3-(4-fluorobenzyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 54);
Bromide salt of 6-(2-cyano-2,2-diphenylethyl)-3-(4-fluorobenzyl)-3-(4- methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 55);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2- carbamoyl^-phenylbutylj-S-azoniabicycloP.l.OJhexane (Compound No. 56); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3- ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 57);
Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 58);
Bromide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-prop-2-en-l-yl-3-azoniabicyclo[3.1.0]hexane (Compound No. 59);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2- diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 60);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)- 3-(cyclopropylmethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 61); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 62);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclohexyl-2- phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 63) ; Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano-
2-cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 64);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclopentyl-2- phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 65);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2-cyclopentyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 66);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(4-cyano-4,4-diphenylbutyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 67);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(4-cyano- 4,4-diphenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 68); Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2- cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 69);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano -3,3-diphenylpropyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 70);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3,3- diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 71);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3,3- diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 72);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3-cyclohexyl-3- phenylpropyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 73); Bromide salt of 3-allyl-3-[2-(l, 3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3- cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 74);
Bromide salt of 3-[2-(l, 3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3- cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 75);
2-({3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}methyl)-2- phenylbutanamide(Compound No. 76);
5-{3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpentanenitrile(Compound No. 77);
5-(3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound No. 78); 5-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound
No. 79);
4-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound No. 80); 4-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound No. 81) or
4-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylbutanenitrile (Compound No. 82).
In another embodiment, there is provided herein a pharmaceutical composition comprising therapeutically effective amount of compound of Formula I or Formula Ia described herein together with one or more pharmaceutically acceptable carrier(s), excipients(s) or diluent(s).
In yet another embodiment there is provided a method for treatment or prophylaxis of a mammal suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors. The method includes administration of at least one compound having the structure of Formula I or Formula Ia.
In yet another embodiment, there is provided a method for treatment or prophylaxis of a mammal suffering from a disease or disorder of the respiratory system such as bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, and the like, urinary system which induce such urinary disorders as urinary incontinence, lower urinary tract symptoms (LUTS), etc. and gastrointestinal system such as irritable bowel syndrome, gastrointestinal hyperkinesis, obesity and diabetes with compounds as described above, wherein the disease or disorder is associated with muscarinic receptors. In yet another embodiment, there is provided a pharmaceutical composition comprising one or more muscarinic receptor antagonist compound having the structure of Formula I or Formula Ia as defined above and at least one or more therapeutic agent selected from histamine antagonist, corticosteroids, beta agonist, leukotriene antagonist, EGFR kinase inhibitors, PAF antagonist, 5-lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p-38 MAP kinase inhibitors. In yet another embodiment, there are provided processes for preparing the compounds as described above.
The following definitions apply to terms as used herein:
The term "alkyl," unless otherwise specified, refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms. Alkyl groups can be optionally interrupted by atom(s) or group(s) independently selected from oxygen, sulfur, a phenylene, sulphinyl, sulphonyl group or -NRα-, wherein Rα can be hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, acyl, aralkyl, -C(=O)ORλ, SOfRψ or -C(=O)NRλRπ. This term can be exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n- decyl, tetradecyl, and the like. Alkyl groups may be substituted further with one or more substituents selected from alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, oxo, thiocarbonyl, sunstituted thiocarbonyl, carboxy, carboxyalkyl, aryl, heterocyclyl, heteroaryl, (heterocyclyl)alkyl, cycloalkoxy, -NRλC(=O)ORλ, COORλ, -CH=N-O(Ci_ ealkyl), -CH=N-NH(Ci_6 alkyl), -CH=N-NH(Ci_6 alkyl)-Ci_6 alkyl, arylthio, thiol, alkylthio, aryloxy, alkoxyamino, nitro, aminosulfonyl, aminocarbonylamino, -NHC(=O)Rλ, -NRλRπ, -C(=O)NRλRπ, -NRλC(=O)NRλRπ, -C(=O)heteroaryl, C(=O)heterocyclyl, -O-C(=O)NRλRπ {wherein Rj1 and Rπ are independently selected from hydrogen, halogen, hydroxy, alkyl, alkenyl, alkynyl, alkenyl, alkoxy, cycloalkyl, cycloalkenyl, aryl, aralkyl, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, carboxy or Rj1 and Rπ may also together join to form a heterocyclyl or heteroaryl ring} or -SOfRψ (wherein £ is an integer from 0-2 and Rψ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl). Unless otherwise constrained by the definition, alkyl substituents may be further substituted by 1-3 substituents selected from alkyl, alkenyl, alkynyl, carboxy, -NRλRπ, -C(=O)NRλRπ, -OC(=O)NRλRπ, - NRλC(=O)NRλRπ, hydroxy, alkoxy, halogen, CF3, cyano, and -SO£Rψ ; or an alkyl group also may be interrupted by 1-5 atoms of groups independently selected from oxygen, sulfur or -NRα- (wherein Rα, Rj1, Rπ, m and Rψ are the same as defined earlier). Unless otherwise constrained by the definition, all substituents may be substituted further by 1-3 substituents selected from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, -NRλRπ, - C(=O)NRλRπ, -O-C(=O)NRλRπ, hydroxy, alkoxy, halogen, CF3, cyano, and -SO£Rψ (wherein Rj1, Rπ, £ and Rψ are the same as defined earlier); or an alkyl group as defined above that has both substituents as defined above and is also interrupted by 1-5 atoms or groups as defined above. The term "alkylene," as used herein, refers to a diradical branched or unbranched saturated hydrocarbon chain having from 1 to 6 carbon atoms and one or more hydrogen can optionally be substituted with alkyl, hydroxy, halogen or oximes. This term can be exemplified by groups such as methylene, ethylene, propylene isomers (e.g., -CH2CH2CH2 and -CH(CHs)CH2) and the like. Alkylene may further be substituted with one or more substituents such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl, acylamino, acyloxy, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryloxy, heteroaryloxy, aminosulfonyl, -COORΨ, -NHC(=O)Rλ, - NRλRπ, -C(=O)NRλRπ, -NHC(=0)NRλRπ, -C(=O)heteroaryl, C(=O)heterocyclyl, -O- C(=O)NRλRπ, nitro, -S(O)£Rλ (wherein Rj1, Rπ, £ and Rψ are the same as defined earlier). Unless otherwise constrained by the definition, all substituents may be further substituted by 1-3 substituents chosen from alkyl, alkenyl, alkynyl, carboxy, -COORΨ, -NRλRπ, - C(=O)NRλRπ, -OC(=O)NRλRπ, -NHC(=0)NRλRπ, hydroxy, alkoxy, halogen, CF3, cyano, and -S(O)£RΨ (wherein Rj1, Rπ, £ and Rψ are the same as defined earlier). Alkylene can also be optionally interrupted by 1-5 atoms of groups independently chosen from oxygen, sulfur and -NRα (wherein Rα is the same as defined earlier). Unless otherwise constrained by the definition, all substituents may be further substituted by 1-3 substituents selected from hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, acyl, aralkyl, alkoxy, hydroxy, carboxy, -C(=O)ORΨ, halogen, CF3, cyano, -NRλRπ, -S(O)£RΨ, -C(=O)NRλRπ, - OC(=O)NRλRπ, -CONH-, -C=O or -C=NOH (wherein Rλ, Rπ, £ and Rψ are the same as defined earlier).
The term "alkenyl," unless otherwise specified, refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group having from 2 to 20 carbon atoms with cis, trans or geminal geometry. Alkenyl groups can be optionally interrupted by atom(s) or group(s) independently chosen from oxygen, sulfur, phenylene, sulphinyl, sulphonyl and -NRα- (wherein Rα is the same as defined earlier). In the event that alkenyl is attached to a heteroatom, the double bond cannot be alpha to the heteroatom. Alkenyl groups may be substituted further with one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, - NHC(=O)Rλ, -NRλRπ, -C(=O)NRλRπ, -NHC(=O)NRλRπ, -O-C(=O)NRλRπ, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, keto, carboxyalkyl, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryl, aralkyl, aryloxy, heterocyclyl, heteroaryl, heterocyclyl alkyl, heteroaryl alkyl, aminosulfonyl, aminocarbonylamino, alkoxyamino, hydroxyamino, alkoxyamino, nitro or SOfRψ (wherein Rj1, Rπ, £ and Rψ are as defined earlier). Unless otherwise constrained by the definition, alkenyl substituents optionally may be substituted further by 1-3 substituents selected from alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkoxy, halogen, -CF3, cyano, -NRλRπ, -C(=O)NRλRπ, -O-
C(=O)NRλRπ and -SOfRψ (wherein Rj1, Rπ, £ and Rψ are as defined earlier). Groups, such as ethenyl or vinyl (CH=CH2), 1-propylene or allyl (-CH2CH=CH2), iso-propylene (- C(CH3)=CH2), bicyclo[2.2.1]heptene, and the like, exemplify this term.
The term "alkynyl," unless otherwise specified, refers to a monoradical of an unsaturated hydrocarbon, having from 2 to 20 carbon atoms. Alkynyl groups can be optionally interrupted by atom(s) or group(s) independently chosen from oxygen, sulfur, phenylene, sulphinyl, sulphonyl and -NRα- (wherein Rα is the same as defined earlier). In the event that alkynyl groups are attached to a heteroatom, the triple bond cannot be alpha to the heteroatom. Alkynyl groups may be substituted further with one or more substituents selected from alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, oxo, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aralkyl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, -NHC(=O)Rλ, -NRλRπ, -NHC(=O)NRλRπ, - C(=O)NRλRπ, -O-C(=O)NRλRπ or -SO£Rψ (wherein Rλ, Rπ, £ and Rψ are the same as defined earlier). Unless otherwise constrained by the definition, alkynyl substituents optionally may be substituted further by 1-3 substituents selected from alkyl, alkenyl, alkynyl, carboxy, carboxyalkyl, hydroxy, alkoxy, halogen, CF3, -NRλRπ, -C(=O)NRλRπ, - NHC(=O)NRλRπ, -C(=O)NRλRπ, cyano or -SO£Rψ (wherein Rλ, Rπ, £ and Rψ are the same as defined earlier). The term "cycloalkyl," unless otherwise specified, refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, which may optionally contain one or more olefinic bonds, unless otherwise constrained by the definition. Such cycloalkyl groups can include, for example, single ring structures, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, and the like or polycyclic ring structures such as, adamantyl, tricyclo[3.3.1.1]decane, bicyclo[2.2.2]octane, bicyclo[4.4.0]decane, bicyclo- [4.3.0]nonane, bicyclo[3.3.0]octane, bicyclo[2.2.1]heptane and the like, or cyclic alkyl groups to which is fused an aryl group, for example, indane, and the like. Spiro and fused ring structures can also be included. Cycloalkyl groups may be substituted further with one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aralkyl, aryloxy, aminosulfonyl, aminocarbonylamino, -NRλRπ, -NHC(=O)NRχRπ, -NHC(=O)Rλ, - C(=O)NRλRπ, -O-C(=O)NRλRπ, nitro, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl or SOfRψ (wherein Rj1, Rπ, £ and Rψ are the same as defined earlier). Unless otherwise constrained by the definition, cycloalkyl substituents optionally may be substituted further by 1-3 substituents selected from alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkoxy, halogen, CF3, -NRλRπ, -C(=O)NRλRπ, -NHC(=0)NRλRπ,- OC(=O)NRλRπ, cyano or -SOfRψ (wherein Rj1, Rπ, £ and Rψ are the same as defined earlier). "Cycloalkylalkyl" refers to alkyl-cycloalkyl group linked through alkyl portion, wherein the alkyl and cycloalkyl are the same as defined earlier.
The term "alkoxy" denotes the group O-alkyl, wherein alkyl is the same as defined above. The term "aryl," unless otherwise specified, refers to aromatic system having 6 to
14 carbon atoms, wherein the ring system can be mono-, bi- or tricyclic and are carbocyclic aromatic groups. For example, aryl groups include, but are not limited to, phenyl, biphenyl, anthryl or naphthyl ring and the like, optionally substituted with 1 to 3 substituents selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, acyl, aryloxy, CF3, cyano, nitro, -CHO, OCF3, -SCF3, COORΨ,
NHC(=0)Rλ, -NRλRπ, C(=N0H)NH2, -C(=0)NRλRπ, -NRλC(=0)NRλRπ, NRλC(=0)0Rλ, -O-C(=O)NRλRπ, -SOfRψ, carboxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, acylamino, thiocarbonyl, substituted thiocarbonyl, amino carbonyl amino, mercapto, haloalkyl, optionally substituted aryl, optionally substituted heterocyclylalkyl, thioalkyl, -C0NHRπ, -0C0Rπ, -C0Rπ, -NHSO2R11 or -SO2NHR11 (wherein Rλ, Rπ, £ and Rψ are the same as defined earlier). Aryl groups optionally may be fused with a cycloalkyl group or a heteroaryl group, wherein the cycloalkyl group may optionally contain heteroatoms selected from O, N or S. Groups such as phenyl, naphthyl, anthryl, biphenyl, and the like exemplify this term.
The term "aralkyl," unless otherwise specified, refers to alkyl-aryl linked through an alkyl portion (wherein alkyl is as defined above) and the alkyl portion contains 1-6 carbon atoms and aryl is as defined below. Examples of aralkyl groups include benzyl, ethylphenyl, propylphenyl, naphthylmethyl and the like.
The term "aryloxy" denotes the group O-aryl, wherein aryl is as defined above. The term "carboxy," as defined herein, refers to -C(=0)0H. The term "heteroaryl," unless otherwise specified, refers to an aromatic monocyclic, bicyclic or a tricyclic ring system (they can be fused, spiro or bridged) containing 1-8 heteroatom(s) independently selected from N, O or S optionally substituted with 1 to 4 substituent(s) selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, acylamino, thiocarbonyl, , substituted thiocarbonyl, thioacyl, oxo, -CHO, -OCF3, -CF3, -SCF3, carboxy, aryl, alkoxy, alkoxyamino, aralkyl, cyano, nitro, heterocyclyl, heteroaryl, -NRλRπ, CH=NOH, -(CH2)wC(=0)Rη ,C00Rλ{wherein w is an integer from 0-4 and Rη is hydrogen, hydroxy, ORλ, NRλRπ, -NH0Rω or -NHOH }, - C(=0)NRλRπ , -NRλC(=0)0Rλ, -NRλC(=O)NRλRπ, -SO£Rψ , -0-C(=0)NRλRπ, -O- C(=O)Rλ, or -O-C(=O)ORλ (wherein £, Rψ, Rx and Rπ are as defined earlier and Rω is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl).
Unless otherwise constrained by the definition, the substituents are attached to a ring atom, i.e., carbon or heteroatom in the ring. Examples of heteroaryl groups includes but are not limited to are benzimidazolyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, benzoxazolyl, benzothiazolyl, benzothienyl, benzo- triazolyl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dioxanyl, dioxolanyl, furyl, homopiperidinyl, imidazolyl, imidazolinyl, imidazolidinyl, indolinyl, indolyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, napthyridinyl, oxazolidinyl, oxazolyl, piperazinyl, piperidinyl, purinyl, pyrazinyl, pyrazolinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, pyrrolopyridinyl, imidazolpyridinyl, quinolinyl, tetrahydrofuranyl, quinozinyl, quinolizinyl, 6H-pyrido-[l,2-α]pyrimidinyl, tetrahydropyranyl, thiazolidinyl, thiazolyl, thienyl, pyridazinyl, carbazolyl, isobenzofuranyl, thianthrene, triazinyl, furanyl, benzofuranyl, tetrazolyl, quinazolinyl, benzoxazinonyl, benzothiazinonyl, benzimidazolone, pyrazolone, xanthene and the like.
The term "halogen or halo" refers to fluorine, chlorine, bromine or iodine.
The term "haloalkyl" refers to alkyl of which one or more hydrogen(s) is/are replaced by halogen.
The term "heterocyclyl," unless otherwise specified, refers to a non-aromatic monocyclic or polycyclic ring (fused, spiro or bridged) system having 1 to 8 heteroatoms selected from O, S or N, and optionally are benzofused or fused heteroaryl having 5-6 ring members and/or optionally are substituted, wherein the substituents are selected from halogen (e.g., F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, acylamino, optionally substituted thiocarbonyl, optionally substituted aryl, alkoxy, alkoxyamino, alkaryl, cyano, nitro, oxo, -CΗO, -OCF3, -CF3, -SCF3, carboxy, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, - 0-C(=0)Rλ, -0-C(=0)0Rλ, -C(=0)NRλRπ, SO£Rψ , -0-C(=0)NRλRπ, -NRλC(=0)0Rλ, - NRλC(=0)NRλRπ, -NRλRπ, mercapto, haloalkyl, thioalkyl, -C00Rψ, -C00NΗRλ, -CORλ,
Figure imgf000017_0001
(wherein £, Rψ, Rj1 and Rπ are as defined earlier) or guanidine. Heterocyclyl can optionally include rings having one or more double bonds. Such ring systems can be mono-, bi- or tricyclic. Carbonyl or sulfonyl group can replace carbon atom(s) of heterocyclyl. Unless otherwise constrained by the definition, the substituents are attached to the ring atom, i.e., carbon or heteroatom in the ring. Also, unless otherwise constrained by the definition, the heterocyclyl ring optionally may contain one or more olefinic bond(s). Examples of heterocyclyl groups includes but are not limited to are tetrahydrofuranyl, dihydrofuranyl, dihydropyridinyl, dihydrobenzofuryl, azabicyclohexyl, dihydroindolyl, piperidinyl, isoxazolinyl, thiazolinyl, thiazolidinonyl, oxazolinyl, oxazolidinonyl, azabicyclo[3.1.0]hexyl, diazabicyclo[2.2.1]heptyl, azetidinyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, dihydrobenzofuryl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dihydroindolyl, dihydroisoxazolyl, dihydropyridinyl, dioxanyl, dioxolanyl, homopiperi- dinyl, imidazolinyl, imidazolidinyl, imidazopyridinyl, indolinyl, indolyl, isoindolel,3-dione, isothiazolidinyl, morpholinyl, napthyridinyl, oxazolidinyl, oxazolyl, phenoxazinyl, phenothiazinyl, piperazinyl, purinyl, pyrazinyl, pyrazolinyl, pyrazolyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, pyrrolopyridinyl, tetrahydropyranyl, tetrazolyl, thiazolidinyl and thiazolyl, and thienyl and the like.
"Heteroarylalkyl" refers to alkyl-heteroaryl group linked through alkyl portion, wherein the alkyl and heteroaryl are as defined earlier.
"Heterocyclylalkyl" refers to alkyl-heterocyclyl group linked through alkyl portion, wherein the alkyl and heterocyclyl are as defined earlier.
"Acyl" refers to -C(=O)R00 wherein R00 is selected from hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl.
The phrase "pharmaceutically acceptable carriers" is intended to include non- toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
The term "Protecting Groups" is used herein to refer to known moieties, which have the desirable property of preventing specific chemical reaction at a site on the molecule undergoing chemical modification intended to be left unaffected by the particular chemical modification. Also the term protecting group, unless or other specified may be used with groups such as hydroxy, amino, carboxy and example of such groups are found in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2nd Edn. John Wiley and Sons, New York, N. Y., which is incorporated herein by reference. The species of the carboxylic protecting groups, amino protecting groups or hydroxy protecting group employed is not so critical so long as the derivatised moiety/moieties is/are stable to conditions of subsequent reactions and can be removed at the appropriate point without disrupting the remainder of the molecule.
The compounds described herein exhibit significant potency in terms of their activity, as determined by in vitro receptor binding and functional assays and in vivo experiments. The compounds that were found active in vitro were tested in vivo. Some of the compounds are potent muscarinic receptor antagonists with high affinity towards M1 and M3 receptors than M2 and/or M5 receptors. Therefore, pharmaceutical compositions for the possible treatment for the disease or disorders associated with muscarinic receptors are provided.
The compounds disclosed herein may be prepared by methods represented by the reaction sequences, shown in Scheme I:
Scheme I
CONH,
-Λ + hal— ( (CH2) -X ,T JN-P amide formation
(CCHH,2)) 4 -t" J .T \ N~-P H2) 4 /T >-P
°2 R1 (When G1 is -CN) M (C
1 Formula Vl Fo
Figure imgf000019_0001
Formula IVb Formula V
The compounds of Formula IV, IVa, IVb, V and VII can be prepared following the procedure as described in Scheme I. The compounds of Formula II (wherein Gi is -CN or -COOalkyl; R1 and R2 are the same as defined earlier) can be reacted with a compound of Formula III (wherein m and T are the same as defined earlier; hal is Cl, Br or I; P is a protecting group, for example, aralkyl, -C(=O)Oaralkyl, -C(=O)OC(CH3)3, - C(=O)OC(CH3)2CHBr2 or -C(=O)OC(CH3)2CC13) to give a compound of Formula IV. The reduction of compound of Formula IV (when Gi is -CN) give a compound of Formula IVa. The hydrolysis of compound of Formula IV (when Gi is -COOalkyl) give a compound of Formula IVb. The deprotection of compound of Formula IV gives a compound of Formula V. The amide formation of compound of Formula IV(when Gi is - CN) gives a compound of Formula VI which on deprotection give a compound of Formula VII.
Compound of Formula II can be reacted with a compound of Formula III to give a compound of Formula IV in one or more organic solvent (for example, dimethylformamide, toluene, tetrahydrofuran, diethylether) in the presence of one or more base (for example, sodium hydride or sodium methoxide).
The reduction of a compound of Formula IV(when Gi is -CN) to give a compound of Formula IVa can be carried out in the presence of reducing agent (for example, lithium aluminum hydride, sodium borohydride, diisobutyl aluminum hydride) in the presence of one or more solvent (for example, diethylether, tetrahydrofuran, dimethylformamide). Alternatively one may also use mixed hydrides (for example, lithium aluminum hydride and aluminum chloride).
The hydrolysis of compound IV (when G1 is -COOalkyl) to give a compound of Formula IVb can be carried out in the presence of one or more base (for example, lithium hydroxide, sodium hydroxide or potassium hydroxide) in the presence of one or more solvent (for example methanol, ethanol or isopropyl alcohol).
The deprotection of a compound of Formula IV (wherein P is aralkyl) to give a compound of Formula V can be carried out in one or more solvent (for example, methanol, ethanol, propanol or isopropyl alcohol) in the presence of a deprotecting agent (for example, palladium on carbon in presence of hydrogen gas or palladium on carbon in ammonium formate solution).
The deprotection of a compound of Formula IV (wherein P is -C(=O)Oaralkyl) to give a compound of Formula V can be carried out in the presence of one or more base (for example, potassium hydroxide, sodium hydroxide or lithium hydroxide) in one or more solvent (for example, methanol, ethanol, propanol or isopropyl alcohol).
Alternatively, the deprotection of a compound of Formula IV (when P is -C(=O)Oaralkyl) to give a compound of Formula V can be carried out in one or more solvent (for example, methanol, ethanol, propanol or isopropylalcohol) in the presence of a deprotecting agent (for example, palladium on carbon in presence of hydrogen gas or palladium on carbon with a source of hydrogen gas (for example, ammonium formate solution, cyclohexene or formic acid)).
The deprotection of a compound of Formula IV (wherein P is -C(=O)OC(CH3)3 or -C(=O)OC(CH3)2CHBr2) to give a compound of Formula V can be carried out in an acidic solution of an alcohol (for example, hydrochloric acid solution of methanol, ethanol, propanol, isopropylalcohol, ethylacetate or diethylether) or trifluoroacetic acid in dichloromethane.
The deprotection of a compound of Formula IV (wherein P is - C(=O)OC(CH3)2CCl3) to give a compound of Formula V can be carried out by a supernucleophile (for example, lithium cobalt (I) phthalocyanine, zinc and acetic acid or cobalt phthalocyanine).
The compound of Formula IV (when Gi is -CN) can be converted to a compound of Formula VI with sulphuric acid.
Alternatively, the conversion of the compound of Formula IV to give a compound of Formula VI may also be carried out with sodium hydroxide in the presence of hydrogen peroxide.
The deprotection of a compound of Formula VI to give a compound of Formula VII can be carried out under similar conditions as for the deprotection of compound of Formula IV to give compound of Formula V. Particular compounds prepared following Scheme I:
3-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanenitrile (Compound
No. 1);
3-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanenitrile (Compound No. 2);
3-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanamide (Compound No. 3);
3-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanamide (Compound No. 4);
Ethyl 3-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanoate (Compound No. 9);
Hydrochloride salt of 3-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2- diphenylpropanoic acid (Compound No. 10);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanenitrile (Compound
No. 14);
S-Q-AzabicycloP^.lloct-S-yl^^-diphenylpropanenitrile (Compound No. 15);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanamide (Compound No. 19); 3-(3-Azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanamide (Compound No. 20);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropan-l-amine (Compound
No. 23);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Comp No. 24);
3-(3-Azabicyclo[3.2.1]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Compound
No. 25);
2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanenitrile (Compound No. 29); 2-(3-Azabicyclo[3.2. l]oct-8-ylmethyl)-2-phenylbutanenitrile (Compound No. 30);
2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanamide (Compound No. 32);
5-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound No. 78);
5-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound No. 79);
4-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound No. 80);
4-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound No. 81).
Scheme Il
Figure imgf000022_0001
The compounds of Formula IX can be prepared following the procedure as depicted in Scheme II. The compound of Formula VIII (wherein R1, R2, R3, m and T are the same as defined earlier) can be reacted with compound of Formula Ra-hal (wherein Ra is alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aralkyl or cycloalkyl and hal is the same as defined earlier) to give a compound of Formula IX.
The compound of Formula VIII can be reacted with a compound of Formula Ra-hal to give a compound of Formula IX in one or more solvent (for example, acetonitrile, dichloromethane, chloroform or carbon tetrachloride) optionally in the presence of one or more base (for example, potassium carbonate, potassium iodide or sodium carbonate).
Particular compounds prepared following Scheme II are:
3-[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]-2,2- diphenylpropanamide (Compound No. 6);
3-{3-[2-(l,3-Benzodioxol-5-yl) ethyl] -3-azabicyclo [3.1.0] hex-6-yl}-2,2- diphenylpropanamide (Compound No. 7);
3-{3-[2-(2,3-Dihydro-l-benzofuran-5-yl) ethyl] -3-azabicyclo [3.1.0] hex-6-yl}- 2,2-diphenylpropanamide (Compound No. 8); 3-{3-[2-(2,3-Dihydro-l-benzofuran-6-yl) ethyl] -3-azabicyclo [3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 16);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 17);
3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanenitrile
(Compound No. 18);
3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanamide (Compound No. 21);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanamide (Compound No. 22);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2-cyclohexyl-2- phenylpropanenitrile (Compound No. 26);
2-({3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}methyl)-2- phenylbutanenitrile (Compound No. 31); 3-[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]-2,2- diphenylpropanenitrile
(Compound No. 36);
2-{[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2- phenylbutanenitrile (Compound No. 37); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanenitrile (Compound No. 38);
2-({3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}methyl)-2- phenylbutanenitrile (Compound No. 39); 2-({3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}methyl)-2- phenylbutanamide(Compound No. 76);
5-{3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpentanenitrile(Compound No. 77); 4-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylbutanenitrile (Compound No. 82).
Also, in all the above representative examples, wherever esters are specified, one skilled in the art could optionally hydrolyze them to their respective acids. For example, hydrolysis of alkyl esters (such as ethyl, methyl or benzyl ester) to their corresponding acids can be carried out in the presence of a base, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide. Alternatively, hydrolysis of benzyl ester can be carried out using catalysts, for example, palladium on carbon or platinum on carbon. The esters such as tert-buty\ can be hydrolyzed to their corresponding acids in the presence of acid, for example, trifluoroacetic acid or hydrochloric acid.
Scheme II I
Quaternization
Figure imgf000024_0001
Figure imgf000024_0002
Formula Villa Formula IXa
The compounds of Formula IXa can be prepared following the procedure as described in Scheme III. The compound of Formula Villa (wherein T, m, R1, R2 and R3 are the same as defined earlier; Rk is alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aralkyl or cycloalkyl) can be reacted with compound of Formula Rv-hal (wherein hal is Br, Cl or I and Rv is alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl or aralkyl) to give compound of Formula IXa
The reaction of a compound of Formula Villa with compound of Formula Rv-hal can be carried out optionally in an organic solvent for example, dichloromethane, dichloroethane, carbon-tetrachloride, chloroform, acetonitrile, methanol or mixture(s) thereof. Particular compounds prepared following Scheme III are:
Iodide salt of 3-[l-(l,3-benzodioxol-5-yl)methyl]-8-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 5);
Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-methyl-3-(4-methylpent-3- en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 11);
Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 12);
Iodide salt of 8-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yljethylJ-S-methyl-S-azoniabicycloP^.lloctane (Compound No. 13); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-cyclohexyl-2- phenylethylj-S-methyl-S-azoniabicycloP^.lloctane (Compound No. 27);
Iodide salt of 3-benzyl-8-(2-cyano-2-cyclohexyl-2-phenylethyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 28);
Iodide salt of 8-[2-(aminocarbonyl)-2-phenylbutyl]-3-benzyl-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 33);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 34);
Iodide salt of 3-benzyl-8-(2-cyano-2-phenylbutyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 35); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 40);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2,2- diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 41);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2,2-diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 42);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 43);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2- phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 44); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano-
2-phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 45);
Bromide salt of -3-benzyl-6- (2-cyano-2,2-diphenylethyl)-3-(4-methylpent-3-en-l- yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 46); Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2,2-diphenylethyl)-3-(4- methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 47);
Iodide salt of 6-(2-cyano-2,2-diphenylethyl)-3-methyl-3-(4-methylpent-3-en-l-yl)- 3-azoniabicyclo[3.1.0]hexane (Compound No. 48) Iodide salt of 6-(2-cyano-2-phenylbutyl)-3-methyl-3-(4-methylpent-3-en-l-yl)-3- azoniabicyclo[3.1.0]hexane (Compound No. 49);
Bromide salt of 3-benzyl-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3-en-l-yl)-3- azoniabicyclo[3.1.0]hexane (Compound No. 50);
Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3- en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 51);
Bromide salt o 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-benzyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 52);
Iodide salt of 6-[2-(aminocarbonyl)-2-phenylbutyl]-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 53); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl) ethyl]-6-(2-cyano-2,2-diphenylethyl)-
3-(4-fluorobenzyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 54);
Bromide salt of 6-(2-cyano-2, 2-diphenylethyl)-3-(4-fluorobenzyl)-3-(4- methylpent-3-en-l-yl)-3-azoniabicyclo [3.1.0] hexane (Compound No. 55);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl) ethyl]-3-(4-bromobenzyl)-6-(2- carbamoyl-2-phenylbutyl)-3-azoniabicyclo [3.1.0] hexane (Compound No. 56);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3- ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 57);
Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 58); Bromide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-prop-2-en-l-yl-3-azoniabicyclo[3.1.0]hexane (Compound No. 59);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2- diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 60);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)- 3-(cyclopropylmethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 61);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 62);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclohexyl-2- phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 63); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2-cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 64);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclopentyl-2- phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 65); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano-
2-cyclopentyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 66);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(4-cyano-4,4-diphenylbutyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 67);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(4-cyano- 4,4-diphenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 68);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2- cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 69);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3,3-diphenylpropyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 70); Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3,3- diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 71);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3,3- diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 72);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3-cyclohexyl-3- phenylpropyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 73);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3- cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 74);
Bromide salt of 3-[2-(l, 3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3- cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 75). In the above schemes, where specific bases, condensing agents, protecting groups, deprotecting agents, solvents, catalysts, temperatures, etc. are mentioned, it is to be understood that other bases, condensing agents, protecting groups, deprotecting agents, solvents, catalysts, temperatures, etc. known to those skilled in the art may be used. Similarly, the reaction temperature and duration may be adjusted according to the desired needs.
Pharmaceutical compositions of the present invention may be administered by following routes, for example, oral, topical, intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, subcutaneous, intranasally, inhalation, rectally or vaginally.
The compounds described herein can be produced and formulated as their enantiomers, diastereomers, N-Oxides, polymorphs, solvates, as well as metabolites having the same type of activity. Pharmaceutical compositions comprising the molecules of Formula I or Formula Ia or metabolites, enantiomers, diastereomers, N-oxides, polymorphs, solvates thereof, in combination with pharmaceutically acceptable carrier and optionally included excipient can also be produced.
Where desired, the compounds of Formula I or Formula Ia and/or their pharmaceutically acceptable solvates, stereoisomers, prodrugs, metabolites, polymorphs or N-oxides may be advantageously used in combination with one or more other therapeutic agents. Examples of other therapeutic agents, which may be used in combination with compounds of Formula I or Formula Ia of this invention and/or their pharmaceutically acceptable solvates, stereoisomers, prodrugs, metabolites, polymorphs or N-oxides include but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5 -lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors and PDE-IV inhibitors.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention. The examples are provided to illustrate particular aspects of the disclosure and do not limit the scope of the present invention as defined by the claims.
Experimental
Synthesis of ethyl diphenyl acetate To a solution of diphenyl acetic acid (1.0 gm) in ethanol (about 20 mL) was added concentrated sulfuric acid (2 mL) and reaction mixture was heated to reflux for about two hours. After the completion of reaction, the reaction mixture was concentrated and residue so obtained was washed with sodium bicarbonate solution. The aqueous layer was extracted with ethyl acetate. The organic layer was separated, washed, dried and concentrated to get the desired compound. Yield: 1.1 g 1H NMR (CDCl3) δ: 7.32-7.23 (1OH, m), 4.23-4.18 (2H, q), 1.27-1.23 (3H, t). Synthesis of cyclopentyKphenyDacetonitrile
To a solution of benzyl cyanide (5.0 g, 42.68 mmol) in anhydrous dimethyl formamide (~ 30 ml) was added sodium hydride (3.4 g) portion wise and stirred the reaction mixture at 25 0C for about thirty minutes. To the resulting reaction mixture was added bromo cyclopentane (6.4g, 42.7 mmol) and stirred the reaction mixture for about twelve hours. The mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 1 % ethyl acetate in hexane as an eluent to furnish the title compound. Yield: 3.3 g.
1H NMR (CDCl3)δ: 7.99-7.96 (IH, m), 7.54-7.52 (IH, m), 7.47-7.44 (2H, m), 7.36-7.32 (IH, m), 3.76-3.68 (IH, m), 1.95-1.58 (9H, m)
Synthesis of cyclohexyKphenyDacetonitrile To the solution of benzyl cyanide (5.0 g, 42.68 mmol) in anhydrous dimethylformamide (~ 30 mL) was added sodium hydride (3.4 g) portionwise and reaction mixture was stirred at 25 0C for about half an hour followed by addition of corresponding bromocyclohexane (6.96 g). The reaction mixture was again stirred at 25 0C for about twelve hours. After the completion of reaction, it was quenched by addition of water and extracted with ethyl acetate. The organic layer was separated, washed with water, brine, dried and concentrated to get the crude compound. The crude compound was purified by column chromatography .Yield: 3.5 g
1H NMR (CDCl3)δ: 7.95-7.92 (IH, m), 7.39-7.27 (4H, m), 3.63-3.61 (IH, m), 1.91-1.19 (HH, m). Synthesis of 2-phenylbutanenitrile
To an aqueous solution of sodium hydroxide (50 %, about 10 mL) were added benzyltriethyl ammonium (97.2 mg) and phenyl acetonitrile (5.0 g, 42.68 mmol) followed by addition of ethyl bromide (4.18 g) slowly at 25 0C. The reaction mixture was stirred at 25 0C for about twelve hours and then at about 40 0C for about twelve hours. After the completion of reaction, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was separated, dried and concentrated to get the crude compound. The crude compound was purified by column chromatography using 2 % ethyl acetate in hexane to furnish the title compound. Yield: 3.2 g 1H NMR (CDCl3)δ: 7.43-7.29 (5H, m), 3.76-3.71 (IH, m) 1.99-1.92 (2H, m), 1.10-1.05 (3H, m).
Synthesis of 3-benzyl-8-(iodomethyl)-3-azabicyclor3.2.11octane
A suspension of triphenyl phosphine (7.9 g) and imidazole (2.0 g) in a mixture of diethyl ether and acetonitrile (~ 80 ml, 3:1) was treated at 0 0C with iodine (7.73 g). The reaction mixture was stirred at 25 0C for about forty five minutes. The reaction mixture was cooled to 0 0C followed by the addition of etheral solution of (3-benzyl-3- azabicyclo[3.2.1]oct-8-yl)methanol (3.2 g, 13.85 mmol). The mixture was stirred at 25 0C for twelve hours. The reaction mixture was quenched by sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure.
The residue thus obtained was purified by column chromatography using 2% ethyl acetate in hexane to furnish the title compound. Yield: 3.8 g.
1H NMR (CDCl3)δ: 7.32-7.21 (5H, m), 3.49 (2H, s), 3.09-3.07 (2H, m), 2.71-2.68 (2H, m), 2.11-2.06 (4H, m), 1.91-1.87 (IH, m), 1.71-1.61 (4H, m). Mass spectrum (m/z, +ve ion mode): 342 (M+l).
Synthesis of 3-benzyl-6-(2-bromoethyl)-3-azabicyclor3. l.Olhexane Step a: S-Benzyl-S-azabicycloP.l.OJhexane-β-carbaldehyde
Dimethyl sulphoxide (123.15 mmol) was added to a solution of oxalyl chloride (61.5 mmol) in dry dichloromethane (-125.0 mL) [precooled to -78 0C under N2 atmosphere]. The reaction mixture was stirred for one hour and followed by the addition of solution of (3-benzyl-3-azabicyclo [3.1.0] hex-6-yl) methanol (24.6 mmol, 5.0 g) in dichloromethane (~ 125.0 mL) dropwise. The reaction mixture was stirred at same temperature for approximately two hours followed by the addition of triethylamine (246.0 mmol). The reaction mixture was further stirred for twenty minutes and then allowed to come to 25 0C and stirred at same temperature for about twelve hours. The solvent was removed under vacuum and residue was partitioned between water and ethyl acetate. The organic layer was separated, washed, dried and concentrated to get the crude compound. The residue thus obtained was purified by column chromatography using 10-15 % ethyl acetate in hexane to furnish the title compound. Yield = 4.2 g;
Mass spectrum (m/z, +ve ion mode): 202 (M+l). Step b: 3-Benzyl-6-vinyl-3-azabicyclo [3.1.0] hexane
To the solution of methyl triphenyl phosphonium iodide (14.92 mmol) in dry tetrahydrofuran (~ 50 mL) under nitrogen atmosphere at -50 0C was added n-butyl lithium (14.92 mmol) and reaction mixture was stirred at -25 0C for about thirty minutes. The solution of the compound obtained from step a above (9.95 mmol, 2.0 g) in dry tetrahydrofuran (15.0 ml) was added to the reaction mixture under nitrogen atmosphere and reaction was stirred at 25 0C for about twelve hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 4% ethyl acetate in hexane to furnish the title compound.
Yield = 900 mg;
Mass spectrum (m/z, +ve ion mode): = 200.2 (M+l) Step c: 2-(3-Benzyl-3-azabicyclo [3.1.0] hex-6-yl) ethanol
To the solution of the compound obtained from step b above (14.0 mmol, 2.8 g) in dry tetrahydrofuran (25.0 ml) at 0 0C under nitrogen atmosphere, borane-tetrahydrofuran complex (BH3-THF) (5.62 mmol) was slowly added and reaction mixture was stirred at 0 0C for thirty minutes followed by heating at 500C for about four hours. The reaction mixture was cooled to 25 0C and sodium hydroxide (6 N, 140.0 ml) was added slowly to reaction mixture followed by dropwise addition of hydrogen peroxide (H2O2) solution (30%, 84.0 mmol). The resulting reaction mixture was stirred at 25 0C for thirty minutes and then heated at 50 0C for about twelve hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 80 % ethyl acetate in hexane as a solvent system to furnish the title compound. Yield = 2.0 g;
Mass spectrum (m/z, +ve ion mode): 218.35 (M+l). Step d: 3-Benzyl-6-(2-bromoethyl)-3-azabicyclo[3.1.0]hexane
To the solution of the compound obtained from step c above (650 mg, 2.99 mmol) in carbon tetrachloride (about 15mL) was added phosphorous tribromide (1.49 mmol) and mixture was reflux for about three hours. The reaction mixture was allowed to cool to 25 0C and subsequently poured slowly into saturated aqueous sodium carbonate. The mixture was extracted with dichloromethane. The organic layer was separated, washed, dried over anhydrous sodium sulphate and concentrated under reduced pressure to furnish the title compound. Yield = 730 mg.
1H NMR (CDCl3)δ: 7.34-7.18 (5H,m), 3.58 (2H,s), 3.46-3.43 (2H,m), 2.96-2.94 (2H,m), 2.35-2.33 (2H,m), 1.96-1.89 (2H,m), 1.33-1.28 (3H,m), 1.15-1.13 (2H,m). Following analogues was prepared similarly
3-Benzyl-6-(bromomethyl)-3-azabicyclo[3.1.0]hexane Synthesis of 3-benzyl-6-(3-bromopropyl)-3-azabicvclor3.1.01hexane Step a: Ethyl (2£>3-(3-benzyl-3-azabicyclo [3.1.0] hex-6-yl)acrylate
Ethyl (triphenylphosphoranylidene) acetate (53.48 mmol) was added to a solution of the S-benzyl-S-azabicycloP.l.OJhexane-ό-carbaldehyde (42.78 mmol, 8.6 g) in benzene (120.0ml) and refluxed the reaction mixture for about six hours and subsequently stirred at 25 0C for about twelve hours. The reaction mixture was concentrated under reduced pressure and residue thus obtained was purified by column chromatography using 6% ethyl acetate in hexane to furnish the desired compound. Yield = 9.7 g. Step b: 3-(3-Benzyl-3-azabicyclo [3.1.0] hex-6-yl) propan-1-ol
To the cold suspension of lithium aluminum hydride (53.13 mmol) in dry tetrahydrofuran (50.0ml) at 0 0C, a solution of ethyl (2£)-3-(3-benzyl-3-azabicyclo [3.1.0] hex-6-yl) acrylate (4.8 g, 17.17 mmol) in tetrahydrofuran (20.0 ml) was added dropwise and reaction mixture was refluxed for about eight hour and then at 25 0C for about twelve hours. The reaction mixture was cooled to -78 0C and quenched with saturated sodium sulphate (Na2SO4) solution. The reaction mixture was filtered over celite and washed with ethyl acetate. The filtrate was dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 3% methanol in dichloromethane to furnish the title compound. Yield = 1.7 g.
Step c: 3-Benzyl-6-(3-bromopropyl)-3-azabicyclo [3.1.0]hexane
The title compound was synthesised following the procedure as mentioned for the synthesis of the compound 3-benzyl-6-(2-bromoethyl)-3-azabicyclo[3.1.0]hexane, step d.
Example 1: Synthesis of 3-(3-benzyl-3-azabicyclor3.1.01hex-6-yl)-2,2- diphenylpropanenitrile (Compound No. 1)
To a solution of diphenyl acetonitrile (commercially available) (500 mg, 2.5 mmol) and 3-benzyl-6-(bromomethyl)-3-azabicyclo[3.1.0]hexane (827mg) in anhydrous dimethylformamide (20.0 ml) under nitrogen atmosphere was cooled at 0 0C followed by the addition of sodium hydride (124 mg) portionwise at the same temperature. The reaction mixture was allowed to stir at 25 0C for about twelve hours. The reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was separated, washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 10% ethyl acetate in hexane as eluent to furnish the title compound. Yield: 290 mg;
1H NMR (CDCl3):δ 7.39-7.17 (15H, m), 3.51 (2H, s) 2.85-2.83 (2H, m), 2.28-2.23 (4H, m), 1.25 1.23 (IH, m) 1.12-1.11 (2H, m);
Mass spectrum (m/z, +ve ion mode): 379.1 (M+l).
Following compound was prepared similarity,
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanenitrile (Compound
No. 14) Mass spectrum (m/z, +ve ion mode): 407.2 (M+l);
3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Compound No. 24)
Mass spectrum (m/z, +ve ion mode): 413.04 (M+l); 2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanenitrile
(Compound No. 29)
Mass spectrum (m/z, +ve ion mode): 359.36 (M+l);
5-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound
No. 79) Mass spectrum (m/z, +ve ion mode): 407.43(M+l);
4-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound
No. 80)
Mass spectrum (m/z, +ve ion mode): 451.40 (M+l).
Example Ia: Synthesis of ethyl 3-(3-benzyl-3-azabicyclor3.1.01hex-6-yl)-2,2- diphenylpropanoate (Compound No. 9)
To a solution of ethyl diphenylacetate (100 mg, 0.42 mmol) in dry toluene (about 10 ml) was added sodium hydride (33.6 mg) followed by the addition of 3-benzyl-6- (bromomethyl)-3-azabicyclo[3.1.0]hexane (110.8 mg). The reaction mixture was refluxed for about six hours which was subsequently quenched by the addition of water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 135 mg. 1H NMR (CDCl3): δ 7.32 7.19 (15 H, m), 4.19-4.13 (2H, m), 3.48 (2H, s), 2.70-2.68 (2H, m), 2.28-2.26 (2H, m), 2.13-2.11 (2H, m), 1.17-1.13 (3H, m), 0.88-0.86 (3H, m);
Mass spectrum (m/z, +ve ion mode): 426.1 (M+l).
Example 2: Synthesis of 3-(3-azabicyclor3.1.01hex-6-yl)-2,2-diphenylpropanenitrile (Compound No. 2) To a solution of the compound No. 1 (330 mg, 0.87 mmol) in methanol (about 10 ml) was added palladium on carbon (20% w/w) and ammonium formate (338 mg) and refluxed the reaction mixture for about one hour. The reaction mixture was cooled to 25 0C and filtered through celite pad. The celite bed was washed with methanol. Filtrate was evaporated under reduced pressure and the residue thus obtained was dissolved in water, basified with aqueous sodium hydroxide solution and extracted with dichloromethane. The organic layer was separated, washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by preparative thin layer chromatography to furnish the title compound. Yield: 52 mg. 1H NMR (CDCl3):δ 7.42-7.30 (1OH, m), 3.31-3.23 (4H, m), 2.35-2.33 (2H, m), 1.54-1.52 (2H, m), 1.16-1.14 (IH, m);
Mass spectrum (m/z, +ve ion mode): 289.2 (M+l).
Following compound were prepared similarily,
3-(3-Azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanenitrile (Compound No. 15) Mass spectrum (m/z, +ve ion mode): 317.15 (M+l);
3-(3-Azabicyclo[3.2.1]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Compound
No. 25)
Mass spectrum (m/z, +ve ion mode): 323.34 (M+l);
2-(3-Azabicyclo[3.2.1]oct-8-ylmethyl)-2-phenylbutanenitrile (Compound No. 30) Mass spectrum (m/z, +ve ion mode): 269.16 (M+l);
5-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound No. 78) Mass spectrum (m/z, +ve ion mode): 317.75 (M+l);
4-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound No. 81) Mass spectrum (m/z, +ve ion mode): 303.32 (M+l). Example 3: Synthesis of 3-(3-benzyl-3-azabicyclor3.1.01hex-6-yl)-2,2- diphenylpropanamide (Compound No. 3)
The compound No. 1 (520 mg) was dissolved in sulphuric acid solution (70 %, 7 ml) and the mixture was heated at about 80 0C for about one hour. The reaction mixture was poured into ice and basified with cold aqueous sodium hydroxide solution. The mixture was extracted with ethyl acetate, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 1 % triethylamine in ethyl acetate as eluent to furnish the title compound. Yield: 105.0 mg.
1H NMR (CDCl3):δ 7.43-7.16 (15H, m), 5.56 (2H, bs), 3.48 (2H, s), 2.72-2.69 (2H, m), 2.32-2.29 (2H, m), 2.17-2.14 (2H, m), 1.14-LI l(IH, m), 0.76 (2H, m); Mass spectrum (m/z, +ve ion mode): 397.21 (M+l).
Example 3a: Synthesis of 3-(3-azabicyclor3.1.01hex-6-yl)-2,2-diphenylpropanamide (Compound No. 4)
The title compound was prepared following the procedure as described in Example 2, by using compound no. 3 (630.0mg) in place of compound No. 1. Yield = 360.0mg 1H NMR (CDCl3):δ 7.39-7.29 (1OH, m), 5.76 (IH, bs, D2O exchangeable), 5.54 (IH, bs, D2O exchangeable), 2.70-2.67 (4H, m), 2.39-2.37 (2H, m), 0.79-0.76 (2H, m), 0.52- 0.47 (IH, m);
Mass spectrum (m/z, +ve ion mode): 307.23 (M+l).
Following analogs were prepared similarly: 3-(3-Azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanamide (Compound No. 20) Mass spectrum (m/z, +ve ion mode): 335.23 (M+l);
Example 4: Synthesis of 3-r3-(4-methylpent-3-en-l-yl)-3-azabicyclor3.1.01hex-6-yll-2,2- diphenylpropanamide (Compound No. 6)
To a solution of the Compound No. 4 (100 mg) and 5-bromo-2-methylpent-2-ene (53.3 mg) in acetonitrile (about 15 ml) was added potassium carbonate (90 mg) and potassium iodide (54 mg) and the reaction mixture was refluxed for about two and half hours. The reaction mixture was concentrated under reduced pressure and the residue thus obtained was diluted with water and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 85% ethyl acetate in hexane and 1% triethylamine as eluent to furnish the title compound. Yield: 134 mg.
1H NMR (CDCl3): δ 7.44-7.30 (1OH, m), 5.54-5.44 (2H, m), 5.01 (IH, s), 2.80-2.77 (2H, m), 2.32-2.23 (3H, m), 2.13-2.04 (5H, m), 1.60-1.57 (6H, m), 1.29- 1.22 (2H, m), 0.74- 0.72 (lH,m);
Mass spectrum (m/z, +ve ion mode): 389.24 (M+l).
Following compounds were prepared similarily.
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanamide (Compound No. 7) Mass spectrum (m/z, +ve ion mode): 454(M+1);
3-{3-[2-(2,3-Dihydro-l-benzofuran-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanamide (Compound No. 8)
Mass spectrum (m/z, +ve ion mode): 453.23 (M+l);
3-{3-[2-(2,3-Dihydro-l-benzofuran-6-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 16)
Mass spectrum (m/z, +ve ion mode): 463.12 (M+l);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 17)
Mass spectrum (m/z, +ve ion mode): 465 (M+l); 3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanenitrile (Compound No. 18)
Mass spectrum (m/z, +ve ion mode): 451.02 (M+l);
3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanamide (Compound No. 21) Mass spectrum (m/z, +ve ion mode): 469.12 (M+l);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanamide (Compound No. 22)
Mass spectrum (m/z, +ve ion mode): 482.93 (M+l); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2-cyclohexyl-2- phenylpropanenitrile (Compound No. 26) Mass spectrum (m/z, +ve ion mode): 470.98 (M+ 1);
2-({3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}methyl)-2- phenylbutanenitrile (Compound No. 31)
Mass spectrum (m/z, +ve ion mode): 416.93 (M+l);
3-[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]-2,2- diphenylpropanenitrile (Compound No. 36) Mass spectrum (m/z, +ve ion mode): 371 (M+l);
2-{[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2- phenylbutanenitrile (Compound No. 37)
Mass spectrum (m/z, +ve ion mode): 323 (M+l);
3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanenitrile (Compound No. 38)
Mass spectrum (m/z, +ve ion mode): 437 (M+l);
2-({3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}methyl)-2- phenylbutanenitrile (Compound No. 39)
Mass spectrum (m/z, +ve ion mode): 389 (M+l); 4-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2-ethyl-2- phenylbutanamide (Compound No. 76)
Mass spectrum (m/z, +ve ion mode): 407 (M+l);
5-{3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpentanenitrile(Compound No. 77) Mass spectrum (m/z, +ve ion mode): 464 (M+l);
4-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylbutanenitrile (Compound No. 82)
Mass spectrum (m/z, +ve ion mode): 451.40 (M+l). Example 5: Synthesis of hydrochloride salt of 3-(3-benzyl-3-azabicyclor3.1.01hex-6-yi)- 2,2-diphenylpropanoic acid (Compound No. 10)
To a solution of the compound no. 9 (78 mg, 153.03 mg) in methanol (about 10 ml) was added aqueous potassium hydroxide solution (30.8 mg) and refluxed the reaction mixture for about twelve hours. The reaction mixture was concentrated under reduced pressure and the residue thus obtained was acidified with aqueous hydrochloric acid solution and extracted with dichloromethane. The organic layer was separated, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. Yield: 59.0 mg. 1H NMR (CDCl3):δ 7.51-7.16 (15H, m), 4.22-2.79 (6H, m), 2.29- 2.27 (2H, m), 1.36-1.24 (3H, m);
Mass spectrum (m/z, +ve ion mode): 398.1(M+1).
Example 6: Synthesis of iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-methyl-3- (4-methylpent-3-en-l-yl)-3-azoniabicyclor3.1.01hexane (Compound No. 11) To a solution of the compound no. 6 (40 mg) in dichloromethane (about 0.5 ml) was added methyl iodide (~3 mL, excess) and stirred the reaction mixture at 25 0C for about twelve hours. The reaction mixture was concentrated under reduced pressure followed by the addition of diethyl ether. The precipitates thus formed were washed with diethyl ether. Supernatant was decanted off and the precipitates were dried under reduced pressure to furnish the title compound. Yield: 55.0 mg.
1H NMR (CD3OD):δ 7.71-7.27 (1OH, m), 5.0 (IH, m), 4.60 (IH, m), 3.51-3.49 (IH, m), 3.15-3.11 (2H, m), 2.94- 2.90 (3H, m), 2.82- 2.79 (2H, m), 2.40-2.35 (4H, m) 1.70 (3H, s), 1.64 (3H, s), 1.41-1.40 (3H, m);
Mass spectrum (m/z, +ve ion mode): 403.20 (M+). Following compound were prepared similarly
Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 12)
Mass spectrum (m/z, +ve ion mode): 469.16 (M+); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 40)
Mass spectrum (m/z, +ve ion mode): 451 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2,2- diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 41)
Mass spectrum (m/z, +ve ion mode): 527 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2,2-diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 42)
Mass spectrum (m/z, +ve ion mode): 607 (M+); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 43)
Mass spectrum (m/z, +ve ion mode): 403 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2- phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 44) Mass spectrum (m/z, +ve ion mode): 479 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2-phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 45)
Mass spectrum (m/z, +ve ion mode): 559 (M+);
Bromide salt of 3-benzyl-6- (2-cyano-2,2-diphenylethyl)-3-(4-methylpent-3-en-l- yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 46)
Mass spectrum (m/z, +ve ion mode): 461 (M+);
Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2,2-diphenylethyl)-3-(4- methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 47)
Mass spectrum (m/z, +ve ion mode): 541 (M+); Iodide salt of 6-(2-cyano-2,2-diphenylethyl)-3-methyl-3-(4-methylpent-3-en-l-yl)-
3-azoniabicyclo[3.1.0]hexane (Compound No. 48)
Mass spectrum (m/z, +ve ion mode): 385 (M+);
Iodide salt of 6-(2-cyano-2-phenylbutyl)-3-methyl-3-(4-methylpent-3-en-l-yl)-3- azoniabicyclo[3.1.0]hexane (Compound No. 49) Mass spectrum (m/z, +ve ion mode): 337 (M+);
Bromide salt of 3-benzyl-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3-en-l-yl)-3- azoniabicyclo[3.1.0]hexane (Compound No. 50)
Mass spectrum (m/z, +ve ion mode): 413 (M+); Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3- en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 51)
Mass spectrum (m/z, +ve ion mode): 492 (M+);
Bromide salt o 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-benzyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 52)
Mass spectrum (m/z, +ve ion mode): 545(M+);
Iodide salt of 6-[2-(aminocarbonyl)-2-phenylbutyl]-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 53)
Mass spectrum (m/z, +ve ion mode): 421 (M+); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-
3-(4-fluorobenzyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 54)
Mass spectrum (m/z, +ve ion mode): 545 (M+);
Bromide salt of 6-(2-cyano-2,2-diphenylethyl)-3-(4-fluorobenzyl)-3-(4- methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 55) Mass spectrum (m/z, +ve ion mode): 479(M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2- carbamoyl^-phenylbutyrj-S-azoniabicycloP.l.OJriexane (Compound No. 56)
Mass spectrum (m/z, +ve ion mode): 576 (M+);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3- ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 57)
Mass spectrum (m/z, +ve ion mode): 465 (M+);
Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 58)
Mass spectrum (m/z, +ve ion mode): 483 (M+); Bromide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-prop-2-en-l-yl-3-azoniabicyclo[3.1.0]hexane (Compound No. 59);
Mass spectrum (m/z, +ve ion mode): 495 (M+);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2- diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 60) Mass spectrum (m/z, +ve ion mode): 477 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)- 3-(cyclopropylmethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 61)
Mass spectrum (m/z, +ve ion mode): 491 (M+); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 62)
Mass spectrum (m/z, +ve ion mode): 479 (M+);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclohexyl-2- phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 63)
Mass spectrum (m/z, +ve ion mode): 457 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2-cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 64)
Mass spectrum (m/z, +ve ion mode): 612 (M+); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclopentyl-2- phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 65)
Mass spectrum (m/z, +ve ion mode): 443 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2-cyclopentyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 66) Mass spectrum (m/z, +ve ion mode): 598 (M+);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(4-cyano-4,4-diphenylbutyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 67)
Mass spectrum (m/z, +ve ion mode): 479 (M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(4-cyano- 4,4-diphenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 68)
Mass spectrum (m/z, +ve ion mode): 634 (M+);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2- cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 69)
Mass spectrum (m/z, +ve ion mode): 483 (M+); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3,3-diphenylpropyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 70)
Mass spectrum (m/z, +ve ion mode): 465 (M+);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3,3- diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 71) Mass spectrum (m/z, +ve ion mode): 491(M+);
Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3,3- diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 72)
Mass spectrum (m/z, +ve ion mode): 541 (M+); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3-cyclohexyl-3- phenylpropyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 73)
Mass spectrum (m/z, +ve ion mode): 471.43 (M+);
Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3- cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 74)
Mass spectrum (m/z, +ve ion mode): 497.44 (M+);
Bromide salt of 3-[2-(l, 3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3- cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 75)
Mass spectrum (m/z, +ve ion mode): 547.51 (M+). Example 6a: Synthesis of iodide salt of 8-(3-amino-3-oxo-2,2-diphenylpropyl)-3-r2-(l,3- benzodioxol-S-yDethyll-S-methyl-S-azoniabicyclorS^.lloctane (Compound No. 13)
To a solution of the compound no. 22 (50 mg) in acetonitrile (~ 1.5 ml) and methanol (- 0.5 ml) was added methyl iodide (0.4 ml) in a sealed vial and stirred the reaction mixture at about 50-60 0C for about forty eight hours. The reaction mixture was concentrated under reduced pressure. The residue so obtain was dissolved in diethyl ether and precipitates thus formed were washed with ether to furnish the title compound. Yield: 45 mg.
1H NMR (CD3OD):δ 7.51-7.30 (1OH, m), 6.78-6.67 (3H, m), 5.93-5.90 (2H, m), 3.64-3.43 (3H, m), 2.46-2.44 (IH, m), 2.28-2.24 (3H, m), 2.02-2.00 (IH, m), Mass spectrum (m/z, +ve ion mode): 497.24 (M+). o 'V 'M 4 U V Following compound were prepared similarly,
Iodide salt of 3-[l-(l,3-benzodioxol-5-yl)methyl]-8-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 5)
Mass spectrum (m/z, +ve ion mode): 465.20 (M+); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-cyclohexyl-2- phenylethylj-S-methyl-S-azoniabicycloP^.lJoctane (Compound No. 27)
Mass spectrum (m/z, +ve ion mode): 485.22 (M+);
Iodide salt of 3-benzyl-8-(2-cyano-2-cyclohexyl-2-phenylethyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 28) Mass spectrum (m/z, +ve ion mode): 427.34 (M+); Iodide salt of 8-[2-(aminocarbonyl)-2-phenylbutyl]-3-benzyl-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 33)
Mass spectrum (m/z, +ve ion mode): 399.17 (M+);
Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 34)
Mass spectrum (m/z, +ve ion mode): 431.28 (M+);
Iodide salt of 3-benzyl-8-(2-cyano-2-phenylbutyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 35)
Mass spectrum (m/z, +ve ion mode): 373.27 (M+). Example 7: Synthesis of 3-(3-Benzyl-3-azabicyclor3.2.11oct-8-yl)-2,2- diphenylpropanamide (Compound No. 19)
To a solution of Compound No. 14 (200 mg) in dichloromethane (about 0.94 ml was added sulphuric acid (90 %, 1.0 mL) and the reaction mixture was stirred at about 40
0C for about twelve hours. After the completion of reaction, reaction mixture was poured into ice and basified with aqueous sodium hydroxide (10%) and extracted with ethyl acetate. The organic layer was separated, washed, dried and concentrated to get the crude compound. The crude compound was purified by column chromatography. Yield: 46.0 mg.
1H NMR (CDCl3) δ: 7.41-7.16 (15H, m), 5.54-5.49 (2H, m), 3.33 (2H, s) 2.47-2.44 (2H, m), 2.24-2.23 2H, m), 1.83-1.72 (3H, m), 1.48-1.45 (IH, m), 1.32-1.24 (4H, m), 0.90-0.88
(IH, m);
Mass spectrum (m/z, +ve ion mode): 425.2 (M+l).
Following compound were prepared similarly,
2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanamide (Compound No. 32)
Mass spectrum (m/z, +ve ion mode): 377.0 (M+l);
Example 8: Synthesis of 3-(3-benzyl-3-azabicvclor3.2.11oct-8-yl)-2,2-diphenylpropan-l- amine (Compound No. 23)
To a suspension of lithium aluminium hydride (92.6 mg) in dry diethylether (15.0ml) was added compound No. 14 (330 mg, 0.81 mmol) slowly and stirred the reaction mixture for about three hours under refluxing. The reaction mixture was cooled to 25 0C which was subsequently quenched with aqueous sodium hydroxide solution. The mixture was filtered through celite pad and washed with ethyl acetate. Filtrate was dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 370 mg.
1H NMR (CDCl3):δ 7.42-7.07 (15H, m), 3.34-3.33 (3H, m), 2.48-2.43 (2H, m), 2.04-2.02 (IH, m), 1.92-1.91 (IH, m), 1.83-1.36 (1OH, m).
Mass spectrum (m/z, +ve ion mode): 411.10 (M+l). Biological Activity Radioligand Binding Assays:
The affinity of test compounds for M1, M2 and M3 muscarinic receptor subtypes was determined by [3H]-N-methylscopolamine binding studies using rat heart and submandibular gland respectively as described by Moriya et al., (Life Sci, 1999,64(25): 2351-2358) with minor modifications. In competition binding studies, specific binding of [3H] ΝMS was also determined using membranes from Chinese hamster ovary (CHO) cells expressing cloned human M1, M2, M3, M4 and M5 receptors. Selectivities were calculated from the Ki values obtained on these human cloned membranes.
Membrane preparation: Submandibular glands and heart were isolated and placed in ice- cold homogenizing buffer (HEPES 2OmM, 1OmM EDTA, pH 7.4) immediately after sacrifice. The tissues were homogenized in 10 volumes of homogenizing buffer and the homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for 10 min. at 4 0C. The supernatant was subsequently centrifuged at 40,00Og for 20 min. at 4 0C. The pellet thus obtained was resuspended in assay buffer (HEPES 20 mM,
EDTA 5mM, pH 7.4) and were stored at -70 C until the time of assay. Ligand binding assay: The compounds were dissolved and diluted in DMSO. The membrane homogenates (150-250 μg protein) were incubated in 250 μl of assay volume
(HEPES 20 mM, pH 7.4) at 24-25 °C for 3h. Non-specific binding was determined in the presence of 1 μM atropine. The incubation was terminated by vacuum filtration over GF/B fiber filters (Wallac). The filters were then washed with ice-cold 5OmM Tris HCl buffer (pH 7.4). The filter mats were dried and bound radioactivity retained on filters was counted. The IC50 & K<j were estimated by using the non- linear curve fitting program using G Pad Prism software. The value of inhibition constant K1 was calculated from competitive binding studies by using Cheng & Prusoff equation (Biochem Pharmacol, 1973,22: 3099-3108), Ki = IC50 /(1+L/Kd), where L is the concentration of [3H]NMS used in the particular experiment. pKi is -log [Ki].
The tested compounds exhibited Ki at m3 receptor is in the range of about 1 nM to about 1000 μM
Functional Experiments using isolated rat bladder Methodology:
Animals were euthanized by overdose of thiopentone and whole bladder was isolated and removed rapidly and placed in ice cold Tyrode buffer with the following composition (mMol/L) NaCl 137; KCl 2.7; CaCl2 1.8; MgCl2 0.1; NaHCO3 11.9; NaH2PO4 0.4; Glucose 5.55 and continuously gassed with 95% O2 and 5 % CO2. The bladder was cut into longitudinal strips (3mm wide and 5-6 mm long) and mounted in 10 ml organ baths at 30 0C, with one end connected to the base of the tissue holder and the other end connected through a force displacement transducer. Each tissue was maintained at a constant basal tension of 1 g and allowed to equilibrate for l1/2 hour during which the Tyrode buffer was changed every 15-20 min. At the end of equilibration period the stabilization of the tissue contractile response was assessed with lμmol/L of carbachol till a reproducible response was obtained. Subsequently a cumulative concentration response curve to carbachol (10~9 mol/L to 3 X 10"4 mol/L) was obtained. After several washes, once the baseline was achieved, cumulative concentration response curve was obtained in presence of NCE (NCE added 20 min. prior to the second cumulative response curve).
The contractile results were expressed as % of control E max. ED50 values are calculated by fitting a non-linear regression curve (Graph Pad Prism). pKb values were calculated by the formula pKb = - log [ (molar concentration of antagonist/ (dose ratio- 1))] where, dose ratio = ED50 in the presence of antagonist/ED50 in the absence of antagonist. In-vitro functional assay Animals and anaesthesia: The Guinea Pig (400-600gm) was procured and trachea was removed under anesthesia (sodium pentobarbital, 300 mg/kg i.p) and was immediately kept it in ice-cold Krebs Henseleit buffer. Indomethacin (lOuM) was present throughout the KH buffer to prevent the formation of bronchoactive prostanoids.
Trachea experiments: The tissue of adherent fascia was cleaned and was cut into strips of equal size (with approx. 4-5 tracheal rings in each strip). The epithelium was removed by careful rubbing, minimizing damage to the smooth muscle. Trachea was opened along the mid-dorsal surface with the smooth muscle band intact and made a series of transverse cuts from alternate sides so that they do not transect the preparation completely. Opposite ends of the cut rings were tied with the help of a thread. The tissue was mounted in isolated tissue baths containing 10ml Krebs Henseleit buffer maintained at 37 0C and bubbled with carbogen, at a basal tension of 1 gm. The buffer was changed 4-5 times for about an hour. The tissue was equilibrated for 1 hr for stabilization. After 1 hr, the tissue was challenged with IuM carbachol. This was repeated after every 2-3 washes till two similar consecutive responses were obtained. At the end of stabilization, the tissue was washed for 30 minutes followed by incubation with suboptimal dose of MRA/Vehicle for 20 minutes prior to contraction of the tissues with lμM carbachol. The contractile response of tissues was recorded either on Powerlab data acquisition system or on Grass polygraph (Model 7). The relaxation was expressed as percentage of maximum carbachol response. The data was expressed as mean ± s.e. mean for n observations. The EC50 was calculated as the concentration producing 50% of the maximum relaxation to lμM carbachol. The percent relaxation was compared between the treated and control tissues using non-parametric unpaired t-test. A p value of < 0.05 was considered to be statistically significant.
The tested compounds exhibited a pKb in the range of about 8.7 to about 10.5 nM In-vitro functional assay to evaluate efficacy of "MRA" in combination with "PDE-IV inhibitors"
Animals and anaesthesia:
Trachea tissue is obtained from a guinea pig (400-600gm) under anesthesia (sodium pentobarbital, 300 mg/kg i.p) and is immediately kept in an ice-cold Krebs Henseleit buffer. Indomethacin (lOuM) is present throughout the KH buffer to prevent the formation of bronchoactive prostanoids.
Trachea experiments:
Trachea tissue is cleaned off adherent fascia and cut it into strips of equal size (with approx. 4-5 tracheal rings in each strip). The epithelium is removed by careful rubbing, minimizing damage to the smooth muscle. The trachea is opened along the mid- dorsal surface with the smooth muscle band intact and a series of transverse cuts is made from alternate sides so that they do not transect the preparation completely. Opposite ends of the cut rings are tied with the help of a thread. The tissue is mounted in isolated tissue baths containing 10 mL Krebs Henseleit buffer maintained at 37°C and is bubbled with carbogen, at a basal tension of 1 gm. The buffer is changed 4-5 times for about an hour and the tissue is equilibrated for 1 hour for stabilization. After 1 hour, the tissue is contacted with IuM carbachol. Repeat this after every 2-3 washes until two similar consecutive responses are obtained. At the end of stabilization, the tissue is washed for 30 minutes followed by incubation with suboptimal dose of MRA/Vehicle for 20 minutes prior to contraction of the tissues with lμM carbachol. The relaxant activity of the PDE- IV inhibitor [10 ^9 M to 10 "4M ] on the stabilized developed tension/response is assessed. The contractile response of tissues is recorded either on a Powerlab data acquisition system or on a Grass polygraph (Model 7). The relaxation is expressed as a percentage of maximum carbachol response. The data is expressed as mean ± s.e. mean for n observations. The EC50 is calculated as the concentration producing 50% of the maximum relaxation to lμM carbachol. The percent relaxation between the treated and control tissues is compared using non-parametric unpaired t-test. A p value of < 0.05 is considered to be statistically significant. In-vivo assay to evaluate efficacy of MRA inhibitors
Male Guinea pigs were anesthetized with urethane (1.5 g/kg, Lp.). Trachea was cannulated along with jugular vein (for carbachol challenge) and animals were placed in the Plethysmograph-Box (PLY 3114 model; Buxco Electronics, Sharon, USA.). Respiratory parameters were recorded using Pulmonary Mechanics Analyzer, Biosystems XA software (Buxco Electronics, USA), which calculated lung resistance (RL) on a breath-by-breath basis. Bronchoconstriction was induced by injections of Carbachol (10 μg/kg) delivered into the jugular vein. Increase in RL over a period of 5 min post carbachol challenge was recorded in presence or absence of MRA or vehicle at 2 hrs and 12 hrs post treatment and expressed as % increase in RLfrom basal.
In-vivo assay to evaluate efficacy of MRA in combination with PDE-IV inhibitors
Drug treatment:
MRA (lμg/kg to lmg/kg) and PDE-IV inhibitor (lμg/kg to lmg/kg) are instilled intratracheally under anesthesia either alone or in combination. Method:
Male wistar rats weighing 200±20gm are used in the study. Rats have free access to food and water. On the day of experiment, animals are exposed to lipopolysaccharide (LPS, lOOμg/ml) for 40 min. One group of vehicle treated rats is exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals are placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing acetylcholine (1, 6, 12, 24, 48 and 96 mg/ml) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone. The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA). Penh, at any chosen dose of acetylcholine is, expressed as percent of PBS response and the using a nonlinear regression analysis PClOO (2 folds of PBS value) values are computed. Percent inhibition is computed using the following formula.
PCIOOLPS - PCIOOTEST % Inhibition = X 100
PCIOOLPS - PClOOpBs Where, PCIOOLPS = PClOO in untreated LPS challenged group PCIOOTEST = PClOO in group treated with a given dose of test compound PClOOpBs = PClOO in group challenged with PBS
Immediately after the airway hyper reactivity response is recorded, animals are sacrificed and bronchoalveolar lavage (BAL) is performed. Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and Neutrophil counts are expressed as cell count (millions cells ml"1 of BAL). Percent inhibition is computed using the following formula.
NCLPS - NCTEST % Inhibition = X 100
NCLPS - NCCON Where, NCLPS = Percentage of neutrophil in untreated LPS challenged group
NCTEST =Percentage of neutrophil in group treated with a given dose of test compound NCCON = Percentage of neutrophil in group not challenged with LPS
1. The percent inhibition data is used to compute ED50 vales using Graph Pad Prism software (Graphpad Software Inc., USA). In-vivo assay to evaluate efficacy of MRA in combination with Corticosteroids
Ovalbumin induced airway inflammation:
Guinea pigs are sensitized on days 0, 7 and 14 with 50-μg ovalbumin and 10 mg aluminum hydroxide injected intraperitoneally. On days 19 and 20 guinea pigs are exposed to 0.1% w v"1 ovalbumin or PBS for 10 min, and with 1% ovalbumin for 30 min on day 21. Guinea pigs are treated with test compound (0.1, 0.3 and 1 mg kg"1) or standard 1 mg kg"1 or vehicle once daily from day 19 and continued for 4 days. Ovalbumin / PBS challenge is performed 2 hours after different drug treatment.
Twenty four hours after the final ovalbumin challenge BAL is performed using Hank's balanced salt solution (HBSS). Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Pellet is collected and resuspended in ImI HBSS. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and eosinophil count are expressed as cell count (millions cells ml"1 of BAL). Eosinophil is also expressed as percent of total leukocyte count. % inhibition is computed using the following formula.
EOSOVA - EOSTEST % Inhibition = X 100
EOSOVA - EoscoN Where,
EOSOVA = Percentage of eosinophil in untreated ovalbumin challenged group
EOSTEST =Percentage of eosinophil in group treated with a given dose of test compound
EoscoN = Percentage of eosinophil in group not challenged with ovalbumin.
In-vivo assay to evaluate efficacy of "MRA" in combination with p38 MAP Kinase inhibitors
Lipopoly saccharide (LPS) induced airway hyper reactivity (AHR) and neutrophilia:
Drug treatment:
MRA (lμg/kg to lmg/kg) and p38 MAP kinase inhibitor (lμg/kg to lmg/kg) are instilled intratracheally under anesthesia either alone or in combination.
Method:
Male wistar rats weighing 200±20gm are used in the study. Rats have free access to food and water. On the day of experiment, animals are exposed to lipopoly saccharide (LPS, lOOμg/ml) for 40 min. One group of vehicle treated rats is exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals are placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing acetylcholine (1, 6, 12, 24, 48 and 96 mg/ml) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone. The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA). Penh, at any chosen dose of acetylcholine is, expressed as percent of PBS response and the using a nonlinear regression analysis PClOO (2 folds of PBS value) values are computed. Percent inhibition is computed using the following formula.
PCIOOLPS - PCIOOTEST
% Inhibition = X 100
PCIOOLPS - PC100PBS Where,
PCIOOLPS = PClOO in untreated LPS challenged group PCIOOTEST = PClOO in group treated with a given dose of test compound PClOOpBs = PClOO in group challenged with PBS
Immediately after the airway hyper reactivity response is recorded, animals are sacrificed and bronchoalveolar lavage (BAL) is performed. Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Pellet is collected and resuspended in ImI HBSS. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and Neutrophil counts are expressed as cell count (millions cells ml"1 of BAL). Percent inhibition is computed using the following formula.
NCLPS — NCTEST % Inhibition = X 100
NCLPS - NCCON Where,
NCLPS = Percentage of neutrophil in untreated LPS challenged group NCTEST =Percentage of neutrophil in group treated with a given dose of test compound NCCON = Percentage of neutrophil in group not challenged with LPS
The percent inhibition data is used to compute ED50 values using Graph Pad Prism software (Graphpad Software Inc. ,USA).
In-vivo assay to evaluate efficacy of "MRA" in combination with β2-agonists
Drug treatment: MRA (lμg/kg to lmg/kg) and long acting β2 agonist is instilled intratracheally under anesthesia either alone or in combination.
Method
Wistar rats (250-350gm) or balb/C mice (20-30gm) is placed in body box of a whole body plethysmograph (Buxco Electronics., USA) to induce bronchoconstriction. Animals are allowed to acclimatize in the body box and are given successive challenges, each of 2 min duration, with PBS (vehicle for acetylcholine) or acetylcholine (i.e. 24, 48, 96, 144, 384, and 768 mg/ml). The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA) for 3 min. A gap of 2 min is allowed for the animals to recover and then challenged with the next higher dose of acetylcholine (ACh). This step is repeated until Penh of rats attained 2 times the value (PC-100) seen with PBS challenge. Following PBS/ACh challenge, Penh values (index of airway resistance) in each rat/mice is obtained in the presence of PBS and different doses of ACh. Penh, at any chosen dose of ACh is, expressed as percent of PBS response. The Penh values thus calculated are fed into Graph Pad Prism software (Graphpad Software Inc., USA) and using a nonlinear regression analysis PClOO (2 folds of PBS value) values are computed. % inhibition is computed using the following formula.
PCIOOTEST - PCIOOCON % Inhibition = X 100 768 - PClOOcoN
Where,
PClOOcoN = PClOO in vehicle treated group
PCIOOTEST = PClOO in group treated with a given dose of test compound
768 = is the maximum amount of acetylcholine used. While the present invention has been described in terms of its specific embodiments, certain modification and equivalents will be apparent to those skilled in the art and are intended.

Claims

We Claim: 1. Compounds having the structure of Formula I or Ia:
Figure imgf000054_0001
Formula I Formula Ia wherein
Figure imgf000054_0002
represents a nitrogen containing cyclic ring having 5-9 carbon atoms and T is a bridging group selected from the group consisting of -(CH2)n-, -CH(Q)CH2-, - CH2CH(Q)CH2-, -CH(Q)-, -CH2-O-CH2- or -CH2-NH-CH2-; n is an integer selected from 0-3 (wherein when n is zero then T represents a direct bond); Q is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl or heterocyclylalkyl; m is an integer selected from 1-4; Ri and R2 are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl; R3 is cyano, -CONRxR5,, -COORx, hydroxy, alkoxy, -(CH2)mORx, -(CH2)m0C0Rx, -(CH2)mNHRx, -(CH2)mNHC0Rx, -(CH2)mNRxSO2Rw; Rx and Ry are independently selected from hydrogen, alkyl, cycloalkyl, aryl, halogen, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; Rx and Ry may also together join to form a heterocyclyl ring; Rz is hydrogen, Rq, alkoxy, aryloxy, -C(=0)NRxRy, -0C(=0)NRxRy, -COOR2, - SO2R3, -NRwSO2Rw, -CN, acyl, -NRxC(=0)0Ry, halogen, hydroxy or - NHC(=O)RW; Rw is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl or heteroarylalkyl; Rq is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl or aralkyl; R1 is alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl or aralkyl; Z" is an anion selected from bromide, chloride, iodide, tartrate, sulphate, phosphate, nitrate, carbonate, fumarate, glutamate, citrate, methanesulphonate, benzenesulphonate, maleate and succinate. 2. A compound selected from the group consisting of: 3-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanenitrile (Compound No. 1); 3-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanenitrile (Compound No. 2); 3-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanamide (Compound No. 3); 3-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanamide (Compound No. 4); Iodide salt of 3-[l-(l,3-benzodioxol-5-yl)methyl]-8-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 5); 3-[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]-2,2- diphenylpropanamide (Compound No. 6); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanamide (Compound No. 7); 3-{3-[2-(2,3-Dihydro-l-benzofuran-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanamide (Compound No. 8); Ethyl 3-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpropanoate (Compound No. 9); Hydrochloride salt of 3-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2- diphenylpropanoic acid (Compound No. 10); Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-methyl-3-(4-methylpent-3- en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 11); Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 12); Iodide salt of 8-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5- y^ethyll-S-methyl-S-azoniabicycloP^.lJoctane (Compound No. 13); 3-(3-Benzyl-3-azabicyclo[3.2. l]oct-8-yl)-2,2-diphenylpropanenitrile (Compound No. 14); S-Q-AzabicycloP^.lJoct-S-yl^^-diphenylpropanenitrile (Compound No. 15); 3-{3-[2-(2,3-Dihydro-l-benzofuran-6-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 16); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanenitrile (Compound No. 17); 3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanenitrile (Compound No. 18); 3-(3-Benzyl-3-azabicyclo[3.2. l]oct-8-yl)-2,2-diphenylpropanamide (Compound No. 19); 3-(3-Azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropanamide (Compound No. 20); 3-[3-(l,3-Benzodioxol-5-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]-2,2- diphenylpropanamide (Compound No. 21); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2,2- diphenylpropanamide (Compound No. 22); 3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2,2-diphenylpropan-l-amine (Compound No. 23); 3-(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Comp No. 24); 3-(3-Azabicyclo[3.2. l]oct-8-yl)-2-cyclohexyl-2-phenylpropanenitrile (Compound No. 25); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}-2-cyclohexyl-2- phenylpropanenitrile (Compound No. 26); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-cyclohexyl-2- phenylethylj-S-methyl-S-azoniabicycloP^.lJoctane (Compound No. 27); Iodide salt of 3-benzyl-8-(2-cyano-2-cyclohexyl-2-phenylethyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 28); 2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanenitrile (Compound No. 29); 2-(3-Azabicyclo[3.2.1]oct-8-ylmethyl)-2-phenylbutanenitrile (Compound No. 30); 2-({3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.2.1]oct-8-yl}methyl)-2- phenylbutanenitrile (Compound No. 31); 2-[(3-Benzyl-3-azabicyclo[3.2.1]oct-8-yl)methyl]-2-phenylbutanamide (Compound No. 32); Iodide salt of 8-[2-(aminocarbonyl)-2-phenylbutyl]-3-benzyl-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 33); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 34); Iodide salt of 3-benzyl-8-(2-cyano-2-phenylbutyl)-3-methyl-3- azoniabicyclo[3.2.1]octane (Compound No. 35); 3-[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]-2,2- diphenylpropanenitrile (Compound No. 36); 2-{[3-(4-Methylpent-3-en-l-yl)-3-azabicyclo[3.1.0]hex-6-yl]methyl}-2- phenylbutanenitrile (Compound No. 37); 3-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2- diphenylpropanenitrile (Compound No. 38); 2-({3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}methyl)-2- phenylbutanenitrile (Compound No. 39); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 40); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2,2- diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 41); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2,2-diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 42); Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-phenylbutyl)-3- methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 43); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(2-cyano-2- phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 44); Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano- 2-phenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 45) ; Bromide salt of 3-benzyl-6- (2-cyano-2,2-diphenylethyl)-3-(4-methylpent-3-en-l- yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 46); 90 Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2,2-diphenylethyl)-3-(4-
91 methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 47);
92 Iodide salt of 6-(2-cyano-2, 2-diphenylethyl)-3-methyl-3-(4-methylpent-3-en-l-yl)-
93 3-azoniabicyclo[3.1.0]hexane (Compound No. 48);
94 Iodide salt of 6-(2-cyano-2-phenylbutyl)-3-methyl-3-(4-methylpent-3-en-l-yl)-3-
95 azoniabicyclo[3.1.0]hexane (Compound No. 49);
96 Bromide salt of 3-benzyl-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3-en-l-yl)-3-
97 azoniabicyclo[3.1.0]hexane (Compound No. 50);
98 Bromide salt of 3-(4-bromobenzyl)-6-(2-cyano-2-phenylbutyl)-3-(4-methylpent-3-
99 en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 51);
100 Bromide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5-
101 yl)ethyl]-3-benzyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 52);
102 Iodide salt of 6-[2-(aminocarbonyl)-2-phenylbutyl]-3-[2-(l,3-benzodioxol-5-
103 yl)ethyl]-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 53);
104 Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-
105 3-(4-fluorobenzyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 54);
106 Bromide salt of 6-(2-cyano-2,2-diphenylethyl)-3-(4-fluorobenzyl)-3-(4-
107 methylpent-3-en-l-yl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 55);
108 Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-
109 carbamoyl^-phenylbuty^-S-azoniabicyclofS.l.OJhexane (Compound No. 56);
110 Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-3-
111 ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 57);
112 Iodide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5-
113 yl)ethyl]-3-ethyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 58);
114 Bromide salt of 6-(3-amino-3-oxo-2,2-diphenylpropyl)-3-[2-(l,3-benzodioxol-5-
115 yl)ethyl]-3-prop-2-en-l-yl-3-azoniabicyclo[3.1.0]hexane (Compound No. 59);
116 Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-
117 diphenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 60);
118 Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2,2-diphenylethyl)-
119 3-(cyclopropylmethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 61);
120 Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-8-(2-cyano-2,2-diphenylethyl)-3-
121 methyl-3-azoniabicyclo[3.2.1]octane (Compound No. 62);
122 Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclohexyl-2-
123 phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 63) ; 124 Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano-
125 2-cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 64);
126 Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-cyclopentyl-2-
127 phenylethyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 65);
128 Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(2-cyano-
129 2-cyclopentyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 66);
130 Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(4-cyano-4,4-diphenylbutyl)-3-
131 methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 67);
132 Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(4-bromobenzyl)-6-(4-cyano-
133 4,4-diphenylbutyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 68);
134 Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(2-cyano-2-
135 cyclohexyl-2-phenylethyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 69);
136 Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano
137 -3,3-diphenylpropyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 70);
138 Bromide salt of 3-allyl-3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3,3-
139 diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 71);
140 Bromide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3,3-
141 diphenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 72);
142 Iodide salt of 3-[2-(l,3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3-cyclohexyl-3-
143 phenylpropyl)-3-methyl-3-azoniabicyclo[3.1.0]hexane (Compound No. 73);
144 Bromide salt of 3-allyl-3-[2-(l, 3-benzodioxol-5-yl)ethyl]-6-(3-cyano-3-
145 cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 74);
146 Bromide salt of 3-[2-(l, 3-benzodioxol-5-yl)ethyl]-3-benzyl-6-(3-cyano-3-
147 cyclohexyl-3-phenylpropyl)-3-azoniabicyclo[3.1.0]hexane (Compound No. 75);
148 2-({3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}methyl)-2-
149 phenylbutanamide(Compound No. 76);
150 5-{3-[2-(l,3-benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2-
151 diphenylpentanenitrile(Compound No. 77);
152 5-(3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound No. 78);
153 5-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylpentanenitrile (Compound
154 No. 79);
155 4-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound
156 No. 80); 157 4-(3-Azabicyclo[3.1.0]hex-6-yl)-2,2-diphenylbutanenitrile (Compound No. 81)
158 and
159 4-{3-[2-(l,3-Benzodioxol-5-yl)ethyl]-3-azabicyclo[3.1.0]hex-6-yl}-2,2-
160 diphenylbutanenitrile (Compound No. 82).
161 and enantiomers, diastereomers, N-oxides, polymorphs, solvates thereof.
1 3. A pharmaceutical composition comprising a therapeutically effective amount of a
2 compound as defined in claim 1 or 2 together with one or more pharmaceutically
3 acceptable carriers, excipients or diluents.
1 4. The use of compounds according to claim 1 or 2 or pharmaceutical composition
2 according to claim 3 for the manufacture of medicament for treating or preventing
3 disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease
4 or disorder is mediated through muscarinic receptors, in a mammal.
1 5. The use of the compounds according to claim 4 for the manufacture of medicament
2 for treating or preventing urinary incontinence, lower urinary tract symptoms
3 (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD),
4 pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal
5 hyperkinesis.
6 6. A pharmaceutical composition comprising one or more compounds of I Formula or
7 Formula Ia
Figure imgf000060_0001
Formula I Formula Ia
9 represents a nitrogen containing cyclic ring having 5-9 carbon atoms and
Figure imgf000060_0002
10 T is a bridging group selected from the group consisting of -(CH2)n-, -CH(Q)CH2-,
11 -CH2CH(Q)CH2-, -CH(Q)-, -CH2-O-CH2- or -CH2-NH-CH2-;
12 n is an integer selected from 0-3 (wherein when n is zero then T represents a direct
13 bond);
14 Q is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl,
15 heteroarylalkyl or heterocyclylalkyl; m is an integer selected from 1-4; Ri and R2 are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl; R3 is cyano, -CONRxR5,, -COORx, hydroxy, alkoxy, -(CH2)mORx, -(CH2)m0C0Rx, -(CH2)mNHRx, -(CH2)mNHC0Rx, -(CH2)mNRxSO2Rw; Rx and Ry are independently selected from hydrogen, alkyl, cycloalkyl, aryl, halogen, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; Rx and Ry may also together join to form a heterocyclyl ring; Rz is hydrogen, Rq, alkoxy, aryloxy, -C(=0)NRxRy, -0C(=0)NRxRy, -COOR2, - SO2R3, -NRwSO2Rw, -CN, acyl, -NRxC(=0)0Ry, halogen, hydroxy or - NHC(=O)RW; Rw is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl or heteroarylalkyl; Rq is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl or aralkyl; R1 is alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl or aralkyl; Z" is an anion selected from bromide, chloride, iodide, tartrate, sulphate, phosphate, nitrate, carbonate, fumarate, glutamate, citrate, methanesulphonate, benzenesulphonate, maleate and succinate; and at least one or more therapeutic agent selected from histamine antagonists, corticosteroids, beta agonists, leukotriene antagonists, EGFR kinase inhibitors, PAF antagonists, 5-lipoxygenase inhibitors, chemokine inhibitors, PDE-4 inhibitors or p38 MAP Kinase inhibitors. 7. A process for preparing compounds of Formula IV, IVa, IVb, V and VII, wherein the process comprises: a) reacting a compound of Formula II ,G1
2 Ri
4 Formula Il
5 with a compound of Formula III
Figure imgf000062_0001
β Formula I
7 to give a compound of Formula IV
Figure imgf000062_0002
Formula IV
9 b) reducing a compound of Formula IV (when Gi is -CN) to give a compound
10 of Formula IVa
Figure imgf000062_0003
γ γ Formula IVa
12 c) hydrolyzing a compound of Formula IV (when Gi is -COOalkyl) to give a
13 compound of Formula IVb
Figure imgf000062_0004
14 Formula IVb
15 d) converting a compound of Formula IV (Gi is -CN) to give a compound of
16 Formula VI
Figure imgf000062_0005
18 e) deprotecting a compound of Formula VI to give a compound of Formula
19 VII
Figure imgf000063_0001
Formula VII f) deprotecting a compound of Formula IV to give a compound of Formula V
Figure imgf000063_0002
Formula V wherein hal is Br, Cl or I; P can be aralkyl, -C(=O)Oaralkyl, -C(=O)OC(CH3)3, - C(=O)OC(CH3)2CHBr2, or C(=O)OC(CH3)2CC13; Gi is -CN or -COOalkyl; V y rePresents a nitrogen containing cyclic ring having 5-9 carbon atoms and T is a bridging group selected from the group consisting of -(CH2)I1-, -CH(Q)CH2-, -CH2CH(Q)CH2-, -CH(Q)-, -CH2-O-CH2- or -CH2-NH-CH2-; n is an integer selected from 0-3 (wherein when n is zero then T represents a direct bond); Q is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl or heterocyclylalkyl; m is an integer selected from 1-4; and Ri and R2 are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl. 8. A process for preparing compounds of Formula IX, wherein the process comprises: a) reacting a compound of Formula VIII
Figure imgf000063_0003
Formula VlIl with a compound of Formula Ra-hal to give a compound of Formula IX
Figure imgf000064_0001
wherein hal is Br, Cl or I; Ra is alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclyl, aralkyl or cycloalkyl; V y rePresents a nitrogen containing cyclic ring having 5-9 carbon atoms and T is a bridging group selected from the group consisting of -(CH2)n-, -CH(Q)CH2-, -CH2CH(Q)CH2-, -CH(Q)-, -CH2-O-CH2- or -CH2-NH-CH2-; n is an integer selected from 0-3 (wherein when n is zero then T represents a direct bond); Q is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl or heterocyclylalkyl; m is an integer selected from 1-4; Ri and R2 are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl; R3 is cyano, -CONRxR5,, -COORx, hydroxy, alkoxy, -(CH2)mORx, -(CH2)m0C0Rx, -(CH2)mNHRx, -(CH2)mNHC0Rx, -(CH2)mNRxSO2Rw; Rx and Ry are independently selected from hydrogen, alkyl, cycloalkyl, aryl, halogen, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; Rx and Ry may also together join to form a heterocyclyl ring; and Rw is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl or heteroarylalkyl. 9. A process for preparing compounds of Formula IXa, wherein the process comprises: N-derivatizing a compound of Formula Villa
Figure imgf000065_0001
Form ula Villa with a compound of Formula Rv-hal to give a compound of Formula IXa
Figure imgf000065_0002
Form ula IXa wherein hal is Br, Cl or I Rv is alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl or aralkyl; Rk is alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aralkyl or cycloalkyl; V y rePresents a nitrogen containing cyclic ring having carbon atoms 5-9 and T is a bridging group selected from the group consisting of -(CH2)n-, -CH(Q)CH2-, -CH2CH(Q)CH2-, -CH(Q)-, -CH2-O-CH2- or -CH2-NH-CH2-; n is an integer selected from 0-3 (wherein when n is zero then T represents a direct bond); Q is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl or heterocyclylalkyl; m is an integer selected from 1-4; Ri and R2 are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl or heterocyclylalkyl; R3 is cyano, -CONRxR5,, -COORx, hydroxy, alkoxy, -(CH2)mORx, -(CH2)m0C0Rx, -(CH2VNHRx, -(CH2)mNHC0Rx, -(CH2)mNRxSO2Rw; Rx and Ry are independently selected from hydrogen, alkyl, cycloalkyl, aryl, halogen, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; Rx and Ry may also together join to form a heterocyclyl ring; Rw is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl or heteroarylalkyl; and Z" is an anion selected from bromide, chloride, iodide, tartrate, sulphate, phosphate, nitrate, carbonate, fumarate, glutamate, citrate, methanesulphonate, benzenesulphonate, maleate and succinate.
PCT/IB2008/051088 2007-03-23 2008-03-24 Muscarinic receptor antagonists WO2008117229A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN636/DEL/2007 2007-03-23
IN636DE2007 2007-03-23

Publications (2)

Publication Number Publication Date
WO2008117229A1 true WO2008117229A1 (en) 2008-10-02
WO2008117229A4 WO2008117229A4 (en) 2009-12-17

Family

ID=39564635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/051088 WO2008117229A1 (en) 2007-03-23 2008-03-24 Muscarinic receptor antagonists

Country Status (1)

Country Link
WO (1) WO2008117229A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2019243851A1 (en) * 2018-06-22 2019-12-26 Heptares Therapeutics Limited Bridged compounds as agonists of the muscarinic m1 and/or m4 receptor
CN112585135A (en) * 2018-06-22 2021-03-30 赫普泰雅治疗有限公司 Oxadiazoles as agonists of muscarinic M1 and/or M4 receptors
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN114502540A (en) * 2019-05-31 2022-05-13 医肯纳肿瘤学公司 TEAD inhibitors and uses thereof
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US11834407B2 (en) 2016-10-14 2023-12-05 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934941A1 (en) * 1996-08-09 1999-08-11 Eisai Co., Ltd. Benzopiperidine derivatives
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934941A1 (en) * 1996-08-09 1999-08-11 Eisai Co., Ltd. Benzopiperidine derivatives
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002487454, accession no. 1985:45760 *
YUN, LIUHONG; WEN, GUANGIING; ZHANG, QIKAI: "Anticholinergics: synthesis of 2',2'-diphenylethylazacycloalkane derivatives", YAOXUE XUEBAO, vol. 19, no. 9, 1984, pages 671 - 675 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US11834407B2 (en) 2016-10-14 2023-12-05 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US11773090B2 (en) 2018-06-22 2023-10-03 Heptares Therapeutics Limited Pharmaceutical compounds
US20200002328A1 (en) * 2018-06-22 2020-01-02 Heptares Therapeutics Limited Pharmaceutical compounds
CN112585135A (en) * 2018-06-22 2021-03-30 赫普泰雅治疗有限公司 Oxadiazoles as agonists of muscarinic M1 and/or M4 receptors
WO2019243851A1 (en) * 2018-06-22 2019-12-26 Heptares Therapeutics Limited Bridged compounds as agonists of the muscarinic m1 and/or m4 receptor
TWI822803B (en) * 2018-06-22 2023-11-21 英商海普泰爾思治療公司 Pharmaceutical compounds
CN112585143A (en) * 2018-06-22 2021-03-30 赫普泰雅治疗有限公司 Bridging compounds as agonists of muscarinic M1 and/or M4 receptors
JP7317054B2 (en) 2018-06-22 2023-07-28 ヘプタレス セラピューティクス リミテッド Cross-linking compounds as agonists of muscarinic M1 and/or M4 receptors
AU2019289217B2 (en) * 2018-06-22 2023-08-17 Heptares Therapeutics Limited Bridged compounds as agonists of the muscarinic M1 and/or M4 receptor
US10787447B2 (en) 2018-06-22 2020-09-29 Heptares Therapeutics Limited Pharmaceutical compounds
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists
US11760728B2 (en) 2019-05-31 2023-09-19 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN114502540A (en) * 2019-05-31 2022-05-13 医肯纳肿瘤学公司 TEAD inhibitors and uses thereof
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US11925651B2 (en) 2019-05-31 2024-03-12 Ikena Oncology, Inc. TEAD inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2008117229A4 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
WO2008117229A1 (en) Muscarinic receptor antagonists
US20230265080A1 (en) Modulators of alpha-1 antitrypsin
EP0591333B1 (en) Azanorbornane derivatives
EP1796667A2 (en) Muscarinic receptor antagonists
EP1546099B1 (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
JP2006501236A (en) 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives containing fluoro and sulfonylamino as muscarinic receptor antagonists
EP1797040A1 (en) Muscarinic receptor antagonists
US20090326004A1 (en) Muscarinic receptor antagonists
WO2006016245A1 (en) Muscarinic receptor antagonists
EP1828174A1 (en) Azabicyclic muscarinic receptor antagonists
US20060287380A1 (en) Azabicyclo Derivatives as Muscarinic Receptor Antagonists
WO2007110782A1 (en) Muscarinic receptor antagonists
WO2006035280A1 (en) 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20080319043A1 (en) 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
EP3770148A1 (en) Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
US20090012116A1 (en) Muscarinic Receptor Antagonists
WO2008104955A1 (en) Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
US20100222393A1 (en) Muscarinic receptor antagonists
KR20140042814A (en) New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
WO2008041184A2 (en) Muscarinic receptor antagonists
WO2008029349A2 (en) Muscarinic receptor antagonists
US20080255188A1 (en) Muscarinic Receptor Antagonists
WO2006005980A1 (en) Xanthine derivatives useful as muscarinic receptor antagonists
TW202402761A (en) Process for preparing shp2 inhibitors
EP2129663A2 (en) Muscarinic receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719811

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08719811

Country of ref document: EP

Kind code of ref document: A1